

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>6</sup>:</b> <b>C07H 15/12, C12P 21/06, A61K 39/00, 38/00, C07K 1/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/34873</b> <b>(43) International Publication Date:</b> 7 November 1996 (07.11.96)
<b>(21) International Application Number:</b> PCT/US96/06134 <b>(22) International Filing Date:</b> 1 May 1996 (01.05.96)  <b>(30) Priority Data:</b> 08/431,517 1 May 1995 (01.05.95) US  <b>(71) Applicant:</b> INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).  <b>(72) Inventors:</b> SCOTT, Randal, W.; 13140 Sun-Mohr, Mountain View, CA 94040 (US). MARRA, Marian, N.; 3748 Bret Harte Drive, Redwood City, CA 94061 (US).  <b>(74) Agent:</b> GREGG, Valeta; Fish & Richardson P.C., Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> RECOMBINANT ENDOTOXIN-NEUTRALIZING PROTEINS  <b>(57) Abstract</b>  In general, the invention features a recombinant endotoxin-neutralizing polypeptide (REN <sup>P</sup> ) characterized by (i) an amino acid sequence, (ii) an amino acid sequence and structure that facilitates selective and specific binding to lipopolysaccharide and (iii) once bound to the lipopolysaccharide, provides endotoxin-neutralizing activity. Preferably, the REN <sup>P</sup> is composed of an amino acid sequence similar to, but not identical to, an amino acid sequence of BPI, LBP, or both. preferably, the REN <sup>P</sup> contains an LPS-binding domain derived from the amino acid sequence of BPI, LBP or both. Preferably, the REN <sup>P</sup> s are covalently bound to a molecule which enhances the half-life of the polypeptide. The REN <sup>P</sup> s of the invention can be used in pharmaceutical compositions for therapeutic and prophylactic regimens, as well as in various <i>in vitro</i> and <i>in vivo</i> diagnostic methods.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## RECOMBINANT ENDOTOXIN-NEUTRALIZING PROTEINS

### Field of the Invention

5           This invention relates generally to the field of recombinant, endotoxin-neutralizing proteins, particularly to recombinant proteins which bind endotoxin and block endotoxin-mediated activation of biological systems.

### Background of the Invention

10           Gram-negative infections are a major cause of morbidity and mortality, especially in hospitalized and immunocompromised patients. [Duma, *Am. J. of Med.*, 78 (Suppl. 6A):154-164 (1985); and Kreger et al., *Am. J. Med.*, 68:344-355 (1980)]. Although available antibiotics  
15           are generally effective in inhibiting growth of Gram-negative bacteria, they do not neutralize the pathophysiological effects associated with endotoxins. Endotoxin is a heat stable bacterial toxin composed of  
20           lipopolysaccharides (LPS) released from the outer membrane of Gram-negative bacteria upon lysis [Shenep et al., *J. Infect. Dis.*, 150(3):380-388 (1984)], and is a potent stimulator of the inflammatory response. Endotoxemia occurs when endotoxin enters the bloodstream  
25           resulting in a dramatic systemic inflammatory response.

          Many detrimental *in vivo* effects of LPS result from soluble mediators released by inflammatory cells. [Morrison et al., *Am. J. Pathol.*, 93(2):527-617 (1978)]. Monocytes and neutrophils, which ingest and kill  
30           microorganisms, play a key role in this process. Monocytes and neutrophils respond to endotoxin *in vivo* by releasing soluble proteins with microbicidal,

- 2 -

proteolytic, opsonic, pyrogenic, complement-activating and tissue-damaging effects. These factors mediate many of the pathophysiological effects of endotoxin. For example, tumor necrosis factor (TNF), a cytokine released  
5 by endotoxin-stimulated monocytes, causes fever, shock, and alterations in glucose metabolism and is a potent stimulator of neutrophils. Other cytokines such as IL-1, IL-6, and IL-8 also mediate many of the pathophysiologic effects of LPS, as well as other pathways involving  
10 endothelial cell activation by tissue factor, kininogen, nitric oxide and complement.

Endotoxin-associated disorders result from extra-gastrointestinal exposure to LPS, e.g. administration of LPS-contaminated fluids, or  
15 Gram-negative infections. Endotoxin-associated disorders can also result when the natural epithelial barrier is injured and the normal Gram-negative flora breach this barrier. For example, endotoxin-associated disorders can occur (a) when there is ischemia of the gastrointestinal  
20 tract (e.g., following hemorrhagic shock or during certain surgical procedures), or (b) when systemic or local inflammation causes increased permeability of the gut to endotoxin or Gram-negative organisms. The presence of endotoxin and the resulting inflammatory  
25 response may result, for example, in endotoxemia, systemic inflammatory response syndrome (SIRS), sepsis syndrome, septic shock, disseminated intravascular coagulation (DIC), adult respiratory distress syndrome (ARDS), cardiac dysfunction, organ failure, liver failure  
30 (hepatobiliary dysfunction), brain failure (CNS dysfunction), renal failure, multi-organ failure and shock.

Examples of diseases which can be associated with Gram-negative bacterial infections or endotoxemia include  
35 bacterial meningitis, neonatal sepsis, cystic fibrosis,



- 3 -

inflammatory bowel disease and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal abscess, hemorrhagic shock and disseminated intravascular coagulation. Subjects who are leukopenic or neutropenic, including subjects treated with chemotherapy or immunocompromised subjects (for example with AIDS), are particularly susceptible to bacterial infection and the subsequent effects of endotoxin.

Several therapeutic compounds have been developed to inhibit the toxic effects of endotoxin, including antibacterial LPS-binding agents and anti-LPS antibodies, although each has met with limitations. For example, Polymyxin B (PMB) is a basic polypeptide antibiotic which binds to Lipid A, the most toxic and biologically active component of endotoxin. PMB inhibits endotoxin-mediated activation of neutrophil granule release *in vitro* and is a potential therapeutic agent for Gram-negative infections. However, because of its systemic toxicity, this antibiotic has limited therapeutic use, and is generally used topically. Combination therapy using antibiotics and high doses of methylprednisolone sodium succinate (MPSS) showed more promise as this regimen prevented death in an experimental animal model of Gram-negative sepsis. However, a clinical study using MPSS with antibiotics in treatment of patients having clinical signs of systemic sepsis showed that mortality rates were not significantly different between the treatment and placebo groups [Bone et al., *N. Engl. J. Med.* 317:653 (1987)].

Antibodies that bind endotoxin have been used in the treatment of endotoxemia. For example, hyperimmune human antisera against *E. coli* J5 reduced mortality by 50% in patients with Gram-negative bacteremia and shock [Ziegler et al., *N. Engl. J. Med.* 307:1225 (1982)].

However, attempts to treat Gram-negative sepsis by

- 4 -

administration of anti-LPS monoclonal antibodies met with little or no success [Ziegler et al., *N. Engl. J. Med.* 324:429 (1991); Greenman et al., *JAMA* 266:1097 (1991); Baumgartner et al., *N. Engl. J. Med.* 325:279 (1991)].

5 Another approach to treating endotoxemia involves the use of cytokine blockers, such as IL-1 receptor antagonists and anti-TNF antibodies, as well as the soluble forms of the IL-1 and TNF receptors. However, any given cytokine blocker blocks only the cytokine for  
10 which it is specific, and fails to prevent the action of other cytokines. Furthermore, blocking cytokines may have other deleterious effects.

Two soluble endotoxin-binding proteins, lipopolysaccharide binding protein (LBP) and  
15 bactericidal/permeability-increasing (BPI), play opposing roles *in vivo* in the physiological response to endotoxin. LBP is a soluble LPS receptor found in serum which binds LPS with high affinity via interaction with the Lipid A moiety [Tobias et al. (1986) *J. Exp. Med.* 164:777-793;  
20 Tobias et al. (1989) *J. Biol. Chem.* 264:10867-10871]. LBP-LPS complexes stimulate monocyte activation through interaction with the CD14 receptor on the surface of monocytes, resulting in production of cytokines such as TNF and IL-1 [Wright et al. (1989) *J. Exp. Med.*  
25 170:1231-1241; Wright et al. (1990) *Science* 249:1431]. Thus, LBP acts as a transfer protein in LPS-mediated stimulation of cytokine release. Moreover, LBP increases LPS activity in that a lower concentration of LPS is required to stimulate monocytes in the presence of LBP  
30 than in its absence.

In direct contrast to LBP, BPI binds and neutralizes endotoxin, preventing inflammatory cell activation. BPI, also known as CAP57 and BP  
[Shafar et al., *Infect. Immun.* 45:29 (1984);  
35 Hovde et al., *Infect. Immun.* 54:142 (1986)] is also

- 5 -

bactericidal by virtue of its interaction with the Lipid A moiety of LPS in the bacterial cell wall. BPI binds LPS, disrupts LPS structure and the cell wall, and increases bacterial membrane permeability, resulting in cell death [Weiss et al., J. Biol. Chem, 253:2664-2672 (1978); Weiss et al., Infection and Immunity 38:1149-1153 (1982)]. BPI retains its *in vitro* bactericidal activity after protease cleavage, suggesting that BPI fragments retain activity [Ooi et al., Clinical Research 33(2):567A (1985)]. This observation was confirmed by Ooi et al., who showed that an N-terminal 25 kD fragment of BPI exhibited both the *in vitro* bactericidal and permeability increasing activities [Ooi et al., J. Biol. Chem. 262:14891 (1987)].

#### 15 Molecular Structures of BPI and LBP

The genes encoding BPI and LBP have been cloned [Gray et al. (1989) J. Biol. Chem. 264:9505-9509; Schumann et al., Science 249:1429-1431 (1990)]. BPI and LBP are immunologically cross-reactive, contain a hydrophobic leader sequence, and share significant amino acid sequence homology over the entire length of the molecules, with an overall amino acid sequence identity of 44% [Tobias et al., J. Biol. Chem. 263:13479-13481 (1988); Schumann et al. *supra*]. BPI and LBP each contains three cysteine residues. BPI contains two glycosylation sites; LBP contains five potential glycosylation sites.

BPI is characterized by two distinct domains, an N-terminal domain and a C-terminal domain, which are separated by a proline-rich hinge region. The N-terminal domain of BPI has strong LPS-neutralizing activity, while the C-terminal domain of BPI has modest LPS-neutralizing activity. LBP can also be divided into N- and C-terminal domains, with the C-terminal domain being implicated in

- 6 -

binding of LPS to macrophages and their subsequent activation.

The N- and C-terminal domains of BPI have a striking charge asymmetry that is not shared by LBP. The N-terminal domain of BPI, which is rich in positively charged lysine residues, imparts a predicted pI > 10 to the full-length molecule. In contrast, the C-terminal domain of BPI is only slightly negatively charged. LBP, which is a neutral protein, has no bactericidal activity [Tobias et al., *J. Biol. Chem.* 263:13479 (1988)]. This suggests that the bactericidal activity of BPI results from its overall cationicity.

Table 1 provides a comparison of BPI and LBP structure and function.

- 7 -

Table 1Comparison of BPI and LBP Structure and Function

	BPI	LBP
<b>SYNTHESIS</b>		
Site of synthesis	Neutrophil	Liver
5 Blood concentration	1-10 ng/ml	1-10 µg/ml
<b>STRUCTURE</b>		
Molecular mass	55 kD	60 kD
Glycosylation sites	2	5
Cysteine	3	3
10 <b>EFFECTS ON LPS MEDIATED:</b>		
neutrophil activation	Inhibits	Stimulates
monocyte activation	Inhibits	Stimulates
TNF release	Inhibits	Stimulates
IL-1 release	Inhibits	Stimulates
15 IL-6 release	Inhibits	Stimulates

\* Four cysteines were reported by Schumann et al. [Science 249:1429-1431 (1990)]. Subsequent DNA sequence analysis by the present inventors determined that Schumann's sequence was erroneous and that LBP contains  
 20 only three cysteine residues (see Figure 1).

Therapeutic intervention to block the inflammatory effects of LPS would ameliorate the morbidity and mortality associated with endotoxemia and septic shock. Unfortunately, although BPI binds LPS with high affinity,  
 25 it has an extremely short half-life in vivo, thus limiting its use in therapy. Native LBP has a longer half-life but, upon binding of LPS, elicits a brisk monocyte reaction which can facilitate release of deleterious quantities of cytokines.

- 8 -

Early and specific diagnosis of endotoxin-associated disorders is essential in the identification of patients who have or who are at risk of developing such disorders.

- 5       Precise identification of a site of Gram-negative infection in a patient would assist the clinician in the design and targeting of antibacterial therapy.

          An ideal anti-endotoxin drug candidate and/or LPS detection reagent would have a longer half-life and  
10   effective, high-affinity endotoxin binding/inactivation without monocyte stimulation. There is a clear need in the field for specific diagnostic and therapeutic agents which neutralizes the effects of endotoxin and has an acceptably long half-life *in vivo*. The present invention  
15   addresses these problems.

#### Summary of the Invention

Recombinant proteins are genetically engineered to bind lipopolysaccharide (LPS) such that the endotoxin is inactivated, thus preventing the endotoxin from inducing  
20   the immunological cascade of events associated with endotoxin-related disorders (e.g., activation of monocytes, tumor necrosis factor (TNF) production).

          In general, the invention features a recombinant endotoxin-neutralizing polypeptide (RENP) characterized  
25   by (i) an amino acid sequence, (ii) a sequence and structure that facilitate specific binding to lipopolysaccharide, (iii) provides endotoxin-neutralizing activity upon LPS binding, and (iv) a half-life that is enhanced relative to the half-life of BPI. Preferably,  
30   the RENP is composed of an amino acid sequence similar to, but not identical to, an amino acid sequence of BPI, LBP, or both. Preferably, the RENP contains an LPS-binding domain derived from the amino acid sequence of BPI, LBP, or both. Preferred RENPs are fusion

- 9 -

proteins which bind LPS with the high affinity of BPI, but do not contain the BPI amino acid sequences associated with BPI's short half-life.

Preferably, the RENPs are covalently bound to a molecule which further enhances the half-life of the polypeptide. For example, the half-life enhancing molecule can be an immunoglobulin fragment, a half-life determining portion of LBP or LBP derivative, or polyethylene glycol. In related aspects, the invention features DNA encoding an RENC of the invention, vectors and transformed cells containing DNA encoding an RENC, a method for producing RENPs, and detectably labeled RENPs.

A primary object of the invention is to provide an RENC which binds and inactivates endotoxin, and has a half-life suitable for administration to a patient.

Another object of the invention is to provide a pharmaceutical composition containing a therapeutically effective amount of an RENC for use in treatment of endotoxin-related disorders.

Still another object of the invention is to provide endotoxin-neutralizing proteins for use in the detection of LPS. The RENPs can be bound to a label which can be detected or can be bound to a support for use in LPS-detection assays. LPS can be detected *in vivo* to identify a site of infection in a subject or can be used in an *in vitro* assay to qualitatively or quantitatively detect LPS in a sample.

Another object of the invention is to provide endotoxin-neutralizing proteins that can be used to produce endotoxin-free solutions and tools for use in, for example, various medical applications.

An advantage of the present invention is that the endotoxin-neutralizing proteins have a half-life in serum which is enhanced relative to the half-life of naturally-occurring LPS-binding proteins, and bind LPS.

- 10 -

without triggering a significant, undesirable immune response.

Another advantage of the invention is that the RENPs can be administered to a patient immediately upon  
5 identification of a symptom of an endotoxin-associated disorder.

Another advantage is that the endotoxin-neutralizing proteins can be administered prophylactically to a patient at risk of endotoxic shock  
10 or other LPS-mediated condition.

An advantage of the invention is that various RENPs having binding specificity for LPS for detection of LPS either *in vivo* or *in vitro*.

Another advantage of the invention is that the  
15 RENPs can be attached to a variety of detectable labels.

Yet another advantage of the invention is that the RENPs can be bound to a molecule which can interact with or which can be a portion of a solid support.

These and other objects, advantages and features  
20 of the present invention will become apparent to those persons skilled in the art upon reading the details of the vectors, cell lines and methodology as more fully set forth below.

#### Brief Description of the Drawings

25 Figures 1A-1D are a comparison of the amino acid sequences of human LBP as described by Schumann et al. (LBPa) and as used herein (LBPb).

Figure 2 is a schematic diagram showing the various combinations of BPI, LBP, BPI variants, and/or  
30 LBP variants which can be used to generate an RENPs of the invention.

Figur s 3A-3D show the nucleotide and amino acid sequences of BPI.



- 11 -

Figures 4A-4C show the nucleotide and amino acid sequences of LBP.

Figures 5A-5F are a comparison of the amino acid sequences of BPI and LBP from various species.

5 Figure 6 shows the amino acid sequence of L<sub>1-197</sub>B<sub>200-456</sub> (NCY118).

Figure 7 is a graph showing the effects of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) and B<sub>1-199</sub>L<sub>200-456</sub> (NCY104) on biotinylated BPI binding to LPS.

10 Figure 8 is graph showing the effects of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103), B<sub>1-199</sub>L<sub>200-456</sub> (NCY104), or B<sub>(S351->A)</sub> (NCY105) protein on LPS activity in the chromogenic LAL assay.

Figure 9 is a graph showing FITC-LPS binding to  
15 monocytes in the presence of BPI or L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103).

Figure 10 is a graph showing the effects of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) or B<sub>1-199</sub>L<sub>200-456</sub> (NCY104), on TNF release by LPS in whole blood.

20 Figure 11 is a graph showing clearance of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) or B<sub>1-199</sub>L<sub>200-456</sub> (NCY104) from mouse serum after intravenous injection.

Figure 12 is a graph comparing the efficacy of BPI and L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) in the protection  
25 to endotoxin challenge.

Figures 13A-13C are graphs showing the effects of BPI, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103), L<sub>1-197</sub>B<sub>200-456</sub> (NCY118), L<sub>1-198</sub>B<sub>201-456</sub><sup>FC</sup> (NCY144), L<sub>1-59</sub>B<sub>60-456</sub> (NCY114), L<sub>1-134</sub>B<sub>135-456</sub> (NCY115), L<sub>1-359</sub>B<sub>360-456</sub> (NCY117), and B<sub>CAT9</sub>  
30 (NCY139) on biotinylated BPI binding to LPS.

Figures 14A-14B are graphs showing the effects of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) and B<sub>1-199</sub>L<sub>200-456</sub> (NCY104) on FITC-labeled LPS binding to human peripheral blood monocytes in the presence of 10%

- 12 -

autologous serum (14A) and in the absence of serum and presence of 0.5% human serum albumin (14B).

Figure 15 is a graph comparing the effects of LBP vs. L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103), B<sub>1-199</sub>L<sub>200-456</sub> (NCY104), L<sub>1-359</sub>B<sub>360-456</sub> (NCY117) and PLL (poly-L-lysine) on the stimulation of TNF $\alpha$  release by phorbol ester-induced THP-1 cells in the absence of serum.

Figure 16 is a graph showing the effects of various recombinant-endotoxin neutralizing proteins upon LPS-mediated TNF production in THP-1 cells cultured without serum.

Figures 17A-17H are graphs showing the clearance of: BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103), B<sub>1-199</sub>L<sub>200-456</sub> (NCY104), and L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) (17A); BPI, L<sub>1-59</sub>B<sub>60-456</sub> (NCY114), L<sub>1-134</sub>B<sub>135-456</sub> (NCY115), and B<sub>CAT9</sub> (NCY139) (17B); BPI, LBP, L<sub>1-359</sub>B<sub>360-456</sub> (NCY117) and L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) (17C); and BPI, LBP and L<sub>(1-198)</sub>B<sub>(201-456)</sub>Fc (NCY144) (assayed for both Fc and BPI) in CD-1 mice (17D); LBP, L<sub>1-275</sub>B<sub>278-456</sub> (NCY116), L<sub>1-359</sub>B<sub>360-456</sub> (NCY117), L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) (17E); LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103), L<sub>1-134</sub>B<sub>135-456</sub> (NCY115), L<sub>(1-198)</sub>B<sub>(202-275)</sub>L<sub>(274-456)</sub> (NCY135), and L<sub>(1-134)</sub>B<sub>(136-275)</sub>L<sub>(274-456)</sub> (NCY134) (17F); LBP (NCY102), L<sub>CAT6</sub> (NCY141), L<sub>CAT9</sub> (NCY142), L<sub>CAT15</sub> (NCY143) and BPI (17G); and BPI, L<sub>1-134</sub>B<sub>135-456</sub> (NCY115), and L<sub>1-59</sub>B<sub>60-456</sub> (NCY114) (17H).

Figure 18 is Western blot of BPI and L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) produced in *Pichia pastoris*.

Figure 19 is a graph showing the effects of BPI and L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) (NCY103) on endotoxin activation of monocytes.

Figure 20 is a graph showing the protective effects of L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) to endotoxin challenge in mice.

- 13 -

Description of the Preferred Embodiments

Before the present recombinant endotoxin-neutralizing proteins, methods for providing therapy to a patient suffering from an endotoxin-related disorder, and compositions and method for diagnosis of a condition associated with LPS are described, it is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a recombinant endotoxin-neutralizing protein" includes a plurality of such proteins and reference to "the DNA encoding the recombinant endotoxin-neutralizing protein" includes reference to one or more transformation vectors and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies

- 14 -

which are described in the publications which might be used in connection with the presently described invention.

### Definitions

- 5 By "lipopolysaccharide" or "LPS" is meant a compound composed of a heteropolysaccharide (which contains somatic O antigen) covalently bound to a phospholipid moiety (lipid A). LPS is a major component of the cell wall of Gram-negative bacteria.
- 10 By "endotoxin" is meant a heat-stable toxin associated with the outer membranes of certain Gram-negative bacteria, including the enterobacteria, brucellae, neisseriae, and vibrios. Endotoxin, normally released upon disruption of the bacterial cells, is
- 15 composed of lipopolysaccharide molecules (LPS) and any associated proteins. The phospholipid moiety of LPS, lipid A, is associated with LPS toxicity. When injected in large quantities endotoxin produces hemorrhagic shock and severe diarrhea; smaller amounts cause fever, altered
- 20 resistance to bacterial infection, leukopenia followed by leukocytosis, and numerous other biologic effects. Endotoxin is a type of "bacterial pyrogen," which is any fever-raising bacterial product. The terms "endotoxin," "LPS," and "lipopolysaccharide" as used herein are
- 25 essentially synonymous.
- By "recombinant endotoxin-neutralizing polypeptide", "RENPN" or "recombinant LPS-neutralizing polypeptide" is meant a protein which has been genetically engineered and contains an LPS-binding
- 30 domain. Preferably, such recombinant LPS-binding proteins bind endotoxin, have a relatively long half-life in serum (e.g., compared to bactericidal/permeability increasing (BPI) protein), and elicit no or relatively little of the undesirable inflammatory side effects.

- 15 -

associated with endotoxin and/or binding of LPS to particular naturally occurring endotoxin-binding proteins (e.g., lipopolysaccharide binding (LBP) protein).

"RENPs" of the invention do not occur naturally and are  
5 distinct from those endotoxin-binding proteins that do occur in nature, specifically BPI and LBP.

By "LPS-binding domain" is meant an amino acid sequence which confers specific and selective LPS binding upon a polypeptide.

10 By "high affinity LPS binding" is meant an LPS binding affinity greater than the LPS binding affinity of LBP, preferably about the same or greater than the LPS binding affinity of BPI.

By "endotoxin-neutralizing activity" is meant a  
15 biological activity associated with inhibition of the toxic effects of lipopolysaccharide, e.g., by binding LPS and preventing interaction of LPS with proteins and/or receptors which mediate an undesirable immunological response associated with endotoxin in a mammalian host.

20 By "recombinant" or "genetically engineered" is meant a DNA sequence, or a polypeptide encoded thereby, generated using nucleic acid manipulation techniques (e.g., cloning, PCR, and/or fusion protein techniques). "Recombinant" or "genetically engineered" DNA, and thus  
25 the proteins encoded by such DNAs, do not occur in nature.

By "half-life" is meant the time required for a living tissue, organ, or organism to eliminate one-half of a substance introduced into it.

30 By "molecule which enhances the half-life" or "half-life enhancing molecule" is meant chemical moiety (e.g., bound via a chemical modification) which enhances the biological half-life of a polypeptide with which it is associated relative to the biological half-life of the  
35 parent polypeptide. Chemical moieties include an amino

- 16 -

acid sequenc or protein. For xample, wher a polyethylene glycol (PEG) moiety is covalently bound to a protein so as to increase the half-life of the protein relative to the un-PEGylated parent protein, the PEG moiety is the "molecule which enhances the half-life" of the protein.

By "half-life determining portion" of a polypeptide is meant an amino acid sequence which is associated with the biological half-life of the polypeptide.

By "bactericidal/permeability increasing protein" or "BPI" is meant a naturally occurring or recombinantly expressed protein having the DNA and amino acid sequences shown in Figures 3A-3D.

By "lipopolysaccharide binding protein" or "LBP" is meant a naturally occurring or recombinantly expressed protein having the DNA and amino acid sequences shown in Figures 1A-1D and Figures 4A-4C.

By "BPI variant" is meant a protein having an amino acid sequence similar to, but not identical to, the amino acid sequence of BPI. "BPI variants" (a) bind LPS, (b) competitively bind LPS in the presence of BPI or LBP, and (c) inhibit the LPS-mediated production of  $\text{TNF}\alpha$  by human monocytes. In general, "BPI variants" contain the amino acid sequence of BPI but with at least one of: 1) an amino acid substitution; 2) an amino acid deletion; or 3) an amino acid addition, relative to the BPI amino acid sequence.

By "LBP variant" is meant a protein having an amino acid sequence similar to, but not identical to, the amino acid sequence of LBP. "LBP variants" (a) bind LPS, (b) competitively bind LPS in the presenc of BPI or LBP, and (c) inhibits production of  $\text{TNF}\alpha$  by human monocytes. In general, "LBP variants" contain the amino acid sequence of LBP but with at l ast one of: 1) an amino

- 17 -

acid substitution; 2) an amino acid deletion; or 3) an amino acid addition, relative to the LPB amino acid sequence.

By "detectable label" is meant any molecule  
5 recognized in the art as a means for identifying and/or detecting a protein to which the detectable label is bound. Exemplary "detectable labels" include radionucleotides, fluorescent moieties, biotin, and antigenic molecules (e.g., a polypeptide which is  
10 specifically bound by an anti-polypeptide antibody). "Detectable labels" include a portion of a chimeric protein where a portion of the chimeric protein can be detected by, for example, binding of a detectably labeled antibody or other detectably labeled molecule which  
15 specifically binds the chimeric protein portion.

By "support" is meant a surface to which LPS or an RNP of the invention can be bound and immobilized. Exemplary supports include various biological polymers and non-biological polymers.

20 By "condition associated with endotoxin", "endotoxin associated disorder", or "endotoxin-related disorder" is meant any condition associated with extra-gastrointestinal (e.g., mucosal, blood-borne, closed space) lipopolysaccharide, e.g., a condition  
25 associated with bacteremia or introduction of lipopolysaccharide into the blood stream or onto an extra-gastrointestinal mucosal surface (e.g., the lung). Such disorders include, but are not limited to, endotoxin-related shock, endotoxin-related disseminated  
30 intravascular coagulation, endotoxin-related anemia, endotoxin-related thrombocytopenia, endotoxin-related adult respiratory distress syndrome, endotoxin-related renal failure, endotoxin-related liver disease or hepatitis, systemic immune response syndrome (SIRS)  
35 resulting from Gram-negative infection, Gram-negative

- 18 -

neonatal sepsis, Gram-negative meningitis, Gram-negative pneumonia, neutropenia and/or leucopenia resulting from Gram-negative infection, hemodynamic shock and endotoxin-related pyresis.

5 By "transformation" is meant a permanent genetic change induced in a cell following incorporation of new DNA (i.e., DNA exogenous to the cell). Where the cell is a mammalian cell, the permanent genetic change is generally achieved by introduction of the DNA into the  
10 genome of the cell.

By "transformed cell" is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding a protein of interest.

15 By "promoter" is meant a minimal DNA sequence sufficient to direct transcription. "Promoter" is also meant to encompass those promoter elements sufficient for promoter-dependent gene expression controllable for cell-type specific, tissue-specific or inducible by  
20 external signals or agents; such elements may be located in the 5' or 3' regions of the native gene.

By "operably linked" is meant that a DNA sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate  
25 molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

By "operatively inserted" is meant that the DNA of interest introduced into the cell is positioned adjacent a DNA sequence which directs transcription and  
30 translation of the introduced DNA (i.e., facilitates the production of, e.g., a polypeptide encoded by a DNA of interest).

By "mammalian subject" or "mammalian patient" is meant any mammal for which the therapy of the invention



- 19 -

is desired, including human, bovine, equin , canine, and feline subjects.

The invention will now be described in further detail.

5 Nomenclature used to describe RENPs

In order to facilitate the discussion and description of the RENPs of the invention, each RNP is designated a specific formula to briefly describe the amino acid sequence of the protein, as well as the origin  
10 of specific portions of the protein. The portion of BPI in the recombinant protein is designated with the letter B, followed by an amino acid sequence numbering assignment corresponding to that shown in Figures 5A-5F for human BPI, wherein the mature N-terminus is  
15 designated as residue 1. The portion of LBP in certain LBP variants and chimeras is designated by the letter L, followed by an amino acid sequence numbering assignment corresponding to that shown in Figures 1A-1D for human LBP, wherein the mature N-terminus is designated as  
20 residue 1. To avoid confusion between the erroneous LBP amino acid sequence published by Schumann et al., *supra* (designated LBP-a) and the correct LBP amino acid sequence used in the RENPs of the invention (designated LBP-b) and presented in Figures 1A-1D. The differences  
25 between the DNA and amino acid sequences for "LBP-a" and "LBP-b" are presented in Table 2A below.

As an example of RNP nomenclature, L<sub>1-197</sub>B<sub>200-456</sub> (NCY118) contains amino acid residues 1-199 of LBP fused at the C-terminus of the LBP portion to the N-terminus of  
30 amino acid residues 200-456 of BPI. L<sub>1-197</sub>B<sub>200-456</sub>, shown in Figur 6 has th N-t rminal domain of LBP (having a putativ endotoxin-binding domain) fused to the C-t rminal domain of BPI (having a putative LPS-clearing domain).

- 20 -

In this application, single amino acid residue substitutions are noted in parentheses, wherein the original amino acid residue is indicated (using the standard one letter code for amino acids), followed by the substitute amino acid residue. For example, the BPI variant having an alanine residue substituted for the original serine residue at position 351 (which substitution removes a glycosylation signal) is designated BPI<sub>(S351→A)</sub>. In another example, in

10 B<sub>(DS200→DP)</sub>, a proline residue is substituted for the serine residue at position 200. In this latter example, the amino acid substitution produces a formic acid-cleavable site.

As another example, the RENP LBP-BPI chimera

15 NCY103 is designated L<sub>1-198(I43→V)</sub>B<sub>201-456(D206→N)</sub>. In the recombinant protein, the original isoleucine residue at position 43 of the LBP portion is substituted with a valine residue, and the original asparagine residue at position 206 of the BPI portion is substituted with an

20 aspartate residue. The C-terminus of the LBP amino acid sequence 1-198 having isoleucine substituted at position 43 is covalently bound to the N-terminus of the BPI amino acid sequence 201-456 having valine substituted at position 206.

25 The amino acid substitutions may be substitutions wherein an original amino acid residue at a given position is substituted with the residue at the corresponding position in a different protein. BPI<sub>(X<sub>n</sub>→Y)</sub> is an example of such a substitution, wherein amino acid

30 residue X at position n in BPI is substituted with residue Y which is found at position n in LBP (or rabbit or b vine LBP). "X" and "Y" denote amino acid positions in a primary amino acid s quence. "Y" as us d in this context is not to be confus d with the symbol "Y"

35 d noting th amino acid residue tyrosin . LBP<sub>(X<sub>n</sub>→Y)</sub> is

- 21 -

another example of such a substitution, wherein amino acid residue X at position n in LBP is substituted with residue Y which is found at position n in BPI (or rabbit or bovine BPI).

- 5 Amino acid residue insertion changes are noted in parentheses, by indicating the amino acid residue after which the insertion occurs, followed by the amino acid residue after which the insertion occurs together with the inserted residue or residues. For example,
- 10 B<sub>(D200papain)</sub> indicates that an amino acid sequence for cleavage of the BPI variant by papain is inserted after the aspartic acid at residue position 200.

TABLE 2A

Individual Sequence Differences Between  
Schumann et al. and LBP as Used Herein

15

NUCLEIC ACID		PROTEIN	
Alpha	Beta	Alpha	Beta
A <sub>42</sub>	C <sub>42</sub>	G <sub>129</sub> YCL <sub>132</sub>	V <sub>129</sub> TAS <sub>132</sub>
C <sub>318</sub>	T <sub>318</sub>	S <sub>149</sub>	F <sub>149</sub>
20 G <sub>488</sub>	(np)	A <sub>241</sub>	V <sub>241</sub> MSLP <sub>245</sub>
(np)	C <sub>499</sub>	L <sub>411</sub>	F <sub>411</sub>
T <sub>546</sub>	C <sub>546</sub>		
C <sub>548</sub>	T <sub>548</sub>		
(np)	T <sub>824</sub> CATGAGCCTTC <sub>835</sub>		
25 C <sub>1333</sub>	T <sub>1333</sub>		

(np) = not present in the sequence

- Table 2B describes some exemplary general classes of RENPs of the invention. In the formulas in Table 2B, n represents an amino acid residue position in the mature sequence of BPI or LBP, x represents an amino acid residue in a position which is C-terminal to n in the
- 30

- 22 -

sequenc of BPI or LBP, and y represents an amino acid residue in a position which is C-terminal to x in the sequence of BPI or LBP. The symbols n, x and y denote the amino acid residue positions as they occur in the mature sequence of the native protein, and not necessarily the positions as they occur in the variant protein.

Table 2B

10

Examples of RENPs

	BPI variant (N-terminal frag.)	$B_{1-n}$
	LBP variant (N-terminal frag.)	$L_{1-n}$
	BPI variant (C-terminal frag.)	$B_{n-456}$
	LBP variant (C-terminal frag.)	$L_{n-456}$
15	BPI variant (internal frag.)	$B_{n-x}$
	LBP variant (internal frag.)	$L_{n-x}$
	LBP-BPI chimera	$L_{n-x}B_{(x+1)-y}$
	BPI-LBP chimera	$B_{n-x}L_{(x+1)-y}$
	LBP-BPI chimera	$L_{n-x}B_{(x+1)-456}$
20	BPI-LBP chimera	$B_{n-x}L_{(x+1)-456}$
	LBP-BPI chimera	$L_{1-n}B_{(n+1)-x}$
	BPI-LBP chimera	$B_{1-n}L_{(n+1)-x}$
	LBP-BPI chimera	$L_{1-n}B_{(n+1)-456}$
	BPI-LBP chimera	$B_{1-n}L_{(n+1)-456}$
25	LBP-BPI-LBP chimera	$L_{1-n}B_{(n+1)-x}L_{(x+1)-456}$
	BPI-LBP-BPI chimera	$B_{1-n}L_{(n+1)-x}B_{(x+1)-456}$

All of the constructs in Table 2B can also contain additional molecules which confer an enhanced half-life upon the RENP (e.g., the RENP can be covalently bound to a polyethylene glycol moiety, or a portion of an immunoglobulin protein or other amino acid sequence which confers a half-life increased relative to the unmodified protein). The general scheme for generation of RENPs is outlined in Figure 2.

- 23 -

Production of RENPs

The RENPs of the invention minimally have characteristics associated with (i) specific and high affinity binding to lipopolysaccharide and

5 (ii) endotoxin-neutralizing activity. In general, the amino acid sequence of RENPs is based upon an amino acid sequence of BPI, LBP, or both. However, the amino acid sequences of the RENPs are distinct from that of BPI and LBP, i.e. the RENPs contain amino acid substitutions,

10 deletions, and/or additions relative to the amino acid sequence of BPI or LBP. Thus, the RENPs of the invention contain: 1) amino acid sequences of a naturally-occurring LPS-binding protein (i.e., LBP and/or BPI); and/or 2) amino acid sequences which do not occur

15 within a single naturally-occurring LPS-binding protein (i.e., LBP or BPI). RENPs can thus be similar to, but not identical to, LBP or BPI. For example, the RENPs can be fragments of BPI and/or LBP, as the amino acid sequences of such RENPs are similar to, but not identical

20 to, naturally occurring BPI or LBP. Moreover, the RENPs of the invention generally have biological properties distinct from and advantageous to either BPI or LBP. RENPs of the invention include BPI variants, LBP variants, and chimeric proteins composed of amino acid

25 sequences derived from BPI, LBP, BPI variants, and/or LBP variants.

For example, RENPs can contain an amino acid sequence of BPI, where the BPI amino acid sequence 1) has been altered at a site of glycosylation (e.g., insertion

30 or deletion of a glycosylation site); 2) contains a neutral or anionic amino acid substituted at a cationic residue of the BPI amino acid sequence (cationic substitution variants); 3) contains an amino acid substitution at a position normally occupied by cysteine

35 in the BPI sequence (cysteine substitution variants); 4)

- 24 -

contains an amino acid substitution where the substituted amino acid is the amino acid at the corresponding position in the LBP amino acid sequence; and/or

5) contains an insertion or deletion of one or more secondary structure-altering amino acid residues.

Exemplary BPI variants containing a glycosylation site alteration include BPI variants having an amino acid residue other than serine substituted for the serine residue at position 351 of the BPI amino acid sequence.

10 BPI variants of this type are of the formula

BPI(S351->X), wherein X is any amino acid other than serine. Preferably, the amino acid substituted at position 351 is alanine. Other BPI variants having a glycosylation site deleted can be generated by, for example, other amino acid substitutions within the glycosylation site.

Additional exemplary BPI variants contain a neutral or anionic amino acid substituted at a cationic residue of the BPI amino acid sequence (cationic substitution variants). For example, one or more of the nonconserved positively-charged residues in BPI (i.e., those residues not found at the corresponding positions in LBP) can be substituted with the corresponding residue or residues in LBP, thus rendering BPI less cationic.

25 Preferably, the cationic substitution variant contains an amino acid substitution in at least one of BPI amino acid residue positions 27, 30, 33, 42, 44, 48, 59, 77, 86, 90, 96, 118, 127, 148, 150, 160, 161, 167, 169, 177, 185, or 198. The cationic substitution variant can contain

30 multiple amino acid substitutions. For example, the cationic substitution variant can contain a neutral or anionic residue at 1) BPI amino acid residue positions 27, 30, 33, 42, 44, 48, and 59; 2) BPI amino acid residue positions 77, 86, 90, 96, 118, and 127; 3) BPI amino acid

35 residue positions 148, 150, 160, 161, 167, 169, 177, 185,

- 25 -

and 198; r 4) BPI amino acid residue positions 27, 30, 33, 42, 44, 48, 59, 77, 86, 90, 96, 118, 127, 148, 150, 160, 161, 167, 169, 177, 185, and 198.

Further example BPI variants contain an amino acid substitution at a position normally occupied by cysteine in the BPI sequence (cysteine mutant). The amino acid selected for substitution at this site can be the amino acid in the corresponding position in LBP. For example, a cysteine residue in BPI (which is not conserved in LBP) may be substituted with an alanine residue (the corresponding residue in LBP). Preferably, the amino acid substitution is at a cysteine residue at BPI amino acid residue position 132, 135, or 175. Preferably, alanine or serine is substituted for cysteine. More preferably, alanine is substituted for the cysteine at position 132 of BPI. Cysteine substitution mutants of BPI can prevent aggregation of the resulting RENPs during their production or use.

Another example of a BPI variant includes a BPI variant having an amino acid substitution where the substituted amino acid is the amino acid at the corresponding position in LBP. The amino acid at the corresponding position is determined by aligning the BPI and LBP amino acid sequences so as to maintain the highest level of amino acid sequence identity between the two sequences. For example, an RENP having the formula B<sub>(Q329→S)</sub> contains a substitution of the glutamine at BPI residue position 329 with the serine residue at the corresponding LBP residue position 327 (see Figures 5A-5F).

Additional exemplary BPI variants contain an insertion and deletion of one or more secondary structure-altering amino acid residues. For example, one or more of the nonconserved proline residues in BPI may

- 26 -

be substituted with the corresponding non-proline residue in LBP.

Alternatively, or in addition to the amino acid sequence of BPI and/or a BPI variant, the RENPs can contain an amino acid sequence of LBP, where the LBP amino acid sequence 1) has been altered at a site of glycosylation (e.g., insertion or deletion of a glycosylation site); 2) contains a cationic amino acid substituted at a neutral or anionic amino acid of the LBP amino acid sequence (cationic replacement mutant); 3) contains an amino acid substitution where the substituted amino acid is the amino acid at the corresponding position in the BPI amino acid sequence; and/or 4) contains an insertion or deletion of one or more secondary structure-altering amino acid residues. The LBP DNA and amino acid sequence used in the construction of particular RENPs exemplified herein is the amino acid sequence of human LBP in Figs. 5A-B.

Exemplary LBP variants contain a cationic amino acid substituted at a neutral or anionic amino acid of the LBP amino acid sequence (cationic replacement variant). For example, one or more of the nonconserved amino acid residues in LBP (at a position which corresponds to a positively-charged residue in BPI) may be substituted with the corresponding positively-charged residue in BPI, and thus result in an LBP variant having an increased positive charge, thus enhancing binding to the negatively charged phosphate groups in LPS, and/or facilitating interaction with the negatively charged surfaces of Gram-negative bacteria. Positively-charged residues include, by way of example, lysine, arginine, and histidine. Preferably, the substituted cationic amino acid is at least one of LBP amino acid residue positions 77, 86, 96, 118, 126, 147, 148, 158, 159, 161, 165, 167, 175, 183, or 196. Cationic replacement



- 27 -

variants can contain multiple amino acid residue substitutions at any combination of the amino acid residues recited above.

Other exemplary LBP variants include an LBP  
5 variant having an amino acid substitution where the substituted amino acid is the amino acid at the corresponding position in BPI. For example, L<sub>(A401→D)</sub> contains a substitution of the alanine residue of LBP at position 401 with the aspartic acid residue at the  
10 corresponding BPI residue position 403.

Further exemplary LBP variants contain an insertion or deletion of one or more one or more secondary structure-altering amino acid residues. For example, one or more of the nonconserved amino acid  
15 residues in LBP (at a position which corresponds to a proline in BPI) may be substituted with a proline residue. Preferably, such amino acid alterations alter the secondary structure of the resulting LBP variant so that it is more like the secondary structure of BPI.

20 Preferably, the RENPs of the invention contain at least one LPS-binding domain of BPI, LBP, a BPI variant, and/or a LBP variant. For example, the LPS-binding domain can be derived from BPI and/or LBP amino acid sequences 17-45, 65-99, and/or 141-167. Preferably, the  
25 RENP has an LPS binding affinity that is greater than the LPS binding affinity of LBP, more preferably an LPS binding affinity that is the same or greater than the LPS binding affinity of BPI. Preferably, the RENP has an LPS binding affinity that is about 25-fold to 50-fold,  
30 preferably about 50-fold to 100-fold, more preferably about 100-fold to 300-fold greater than the LPS binding affinity of LBP as determined by LPS binding or LPS binding competition assays. The LPS binding affinity of BPI is about 60-fold to 100-fold greater than the LPS  
35 binding affinity of LBP.

- 28 -

The RENPs can contain multiple LPS-binding domains derived from any of these LPS-binding proteins. For example, an RENP can be a multivalent chimeric protein (i.e., a fusion protein) composed of an LPS-binding domain of BPI covalently bound (i.e., as in a fusion protein) to an LPS-binding domain of LBP. As used herein, a chimera means a protein comprising all or a portion of a first protein fused to all or a portion of a second protein, which resulting fusion protein may in turn be fused to all or a portion of a third protein. Examples of chimeras include, by way of example, (a) a protein comprising a portion of LBP fused to a portion of BPI, (b) a protein comprising a portion of LBP fused to a portion of BPI which portion of BPI is in turn fused to a portion of an immunoglobulin protein, or (c) a protein comprising a portion of LBP fused to a portion of BPI, which is in turn fused to a portion of LBP. Each protein portion of the chimera may comprise a fragment of the protein, a point mutant of the protein (i.e., a variant), a deletion mutant of the protein, or a point and deletion mutant of the protein.

Examples of BPI fragments which can be incorporated into the RENPs of the invention include the BPI amino acid sequences 1-25, 1-85, 1-137, 1-135, 1-147, 1-159, 88-100, 148-161, 137-199, 44-159, 44-199, 135-199, 100-199, 162-199, 100-147. Examples of LBP fragments which can be incorporated into the RENPs of the invention include LBP amino acid sequences 1-43, 1-87, 26-135, 26-134, 86-99, 101-146, 101-197, 135-197, 137-197, 158-197, 160-197, and/or 147-159. The amino acid sequences of BPI and/or LBP can be combined in any order from N- to C-terminus to provide an RENP having sequences derived from BPI and/or LBP. For example, the RENPs can have the sequences B<sub>1-137</sub>L<sub>137-197</sub>, L<sub>1-43</sub>B<sub>44-199</sub>, B<sub>1-159</sub>L<sub>158-197</sub>, B<sub>1-135</sub>L<sub>135-197</sub>, L<sub>1-43</sub>B<sub>44-159</sub>L<sub>158-197</sub>, B<sub>1-25</sub>L<sub>26-135</sub>B<sub>137-199</sub>, B<sub>1-25</sub>L<sub>26-</sub>

- 29 -

134B<sub>135-199</sub>, L<sub>1-87</sub>B<sub>88-100</sub>L<sub>101-146</sub>B<sub>148-161</sub>L<sub>160-197</sub>, B<sub>1-85</sub>L<sub>86-99</sub>B<sub>100-199</sub>, B<sub>1-147</sub>L<sub>147-159</sub>B<sub>162-199</sub>, B<sub>1-85</sub>L<sub>86-99</sub>B<sub>100-147</sub>L<sub>147-159</sub>B<sub>162-199</sub>, L<sub>1-87</sub>B<sub>88-100</sub>L<sub>101-197</sub>, or various combinations of other BPI and/or LBP fragments.

- 5           RENPs can share properties of both BPI and LBP. For example, fusing the N-terminal domain of LBP to the C-terminal domain of BPI results in an RENP which differs from LBP in that the chimera neutralizes endotoxin in whole blood and differs from BPI in that the chimera has
- 10 a longer circulating half-life *in vivo*. Such RENPs have significant diagnostic and therapeutic potential. As per the nomenclature described above, RENPs designated BPI-LBP contain all or a part of the N-terminal domain of BPI fused to all or a part of the C-terminal domain of
- 15 LBP. Likewise, RENPs designated LBP-BPI contain all or a part of the N-terminal domain of LBP fused to all or a part of the C-terminal domain of BPI.

Where the RENP contains amino acid sequences derived from both BPI and LBP, the RENP is preferably

20 composed of a C-terminal fragment of BPI (or a BPI variant) and an N-terminal fragment of LBP (or an LBP variant). Preferably the C-terminal fragment of BPI (or a BPI variant) contains amino acid residues 60-456, 136-456, 199-456, 277-456, 300-456, 200-456, 136-361,

25 136-275, 200-275, or 200-361, more preferably 60-456, more preferably 199-359. The amino acid sequence of BPI from residue 199 to residue 359 contains a region required for neutralizing LPS, i.e., preventing LPS from stimulating an inflammatory response. Preferably, the N-

30 -terminal fragment of LBP (or an LBP variant) contains amino acid residues 1-59, 1-134, 1-164, 1-175, 1-274, 1-359, 1-134, or 1-197, more preferably 1-175. In addition to the specific amino acid sequences of BPI and LBP recited above, the RENP can also contain amino acid

35 residues derived from the C-terminus of LBP (or an LBP

- 30 -

variant), preferably LBP (or LBP variant) amino acid residues 360-456 or 274-456.

Polypeptides which bind LPS can be identified using any of several assays well known in the art such as the 1) chromogenic LAL competition assay, 2) binding to LPS immobilized on a surface, and 3) FITC-LPS assay for binding to macrophages. The ability of a polypeptide to neutralize endotoxin can also be determined using methods well known in the art. Endotoxin neutralization assays include assays to examine the ability of a polypeptide to 1) prevent LPS-induced TNF release in whole blood, 2) inhibit or prevent TNF production by THP-1 cells, 3) provide protection in a mouse endotoxin challenge assay, and 4) reduce or prevent LPS-induced cytokine release and/or mortality in an animal model. Each of these assays are described in detail in the examples section below. The results of the *in vitro* and *in vivo* assays used herein are accepted in the art. The results of these assays are predictive of relevant biological activity *in vivo*, e.g. in humans.

Preferably, the RENPs of the invention have a biological half-life (e.g., serum half-life) which is enhanced relative to the biological half-life of BPI. Preferably, the half-life of the RENP is enhanced relative to BPI such that the clearance time of the RENP is at least 1.5-fold to 10-fold, preferably about 10-fold to 50-fold, more preferably about 50-fold to 100-fold, even more preferably about 100-fold to 350-fold slower than the clearance rate of BPI. The clearance rate values representing these ranges are from about 8 ml/min to 1.5 ml/min, preferably 1.5 ml/min to 0.26 ml/min, more preferably 0.26 ml/min to 0.13 ml/min, and more preferably about 0.13 ml/min to 0.03 ml/min.

To enhance the RENP half-life, the RENP can be covalently bound to a molecule which enhances the

- 31 -

half-life of the polypeptide. The half-life enhancing molecule can be any of a variety of half-life enhancing molecules. Exemplary half-life enhancing molecules include immunoglobulin fragments, a half-life determining portion of LBP, a half-life determining portion of an LBP variant, or polyethylene glycol (PEG), preferably a half-life determining portion of LBP or an LBP variant. Preferably, where the half-life enhancing molecule is a portion of LBP or an LBP variant, the half-life enhancing molecule is derived from the N-terminus of the LBP or LBP variant amino acid sequence, more preferably from amino acid residues 1-59, 1-134, 1-274, 1-359, 1-134, 1-164, 1-175, or 1-197, most preferably 1-164 or 1-175. Methods of attachment of PEG moieties to a protein (i.e., PEGylation) are well known in the art and are exemplified in U.S. patent nos. 4,179,337; 5,166,322; 5,206,344; and PCT application serial no. PCT/US94/11624, published April 28, 1995.

As used herein, an RENP-Ig chimeric protein is an RENP which (i) contains a portion of BPI or LBP (at least 10 amino acid residues in length of (a) BPI, or (b) BPI variant, or (c) LBP, and/or (d) LBP variant) fused at the C-terminus to the N-terminus the Fc portion of an immunoglobulin molecule, and (ii) is capable of (a) binding to LPS, (b) competing with BPI or LBP for binding to LPS, and (c) inhibiting the production of TNF $\alpha$  by human monocytes. For example, the portion of the immunoglobulin molecule is derived from an IgG molecule, specifically from an IgG<sub>1</sub> heavy chain Fc domain. RENP-Ig chimera is a fusion protein composed predominantly of sequences derived from BPI, variant BPI, LBP and/or variant LBP. The term "LBP-BPI-IgG chimera" indicates that the RENP-Ig chimera contains amino acid sequences derived from both BPI (or a BPI variant) and LBP (or an LBP variant).

- 32 -

Identification of a half-life enhancing polypeptide sequence (e.g., a polypeptide derived from an immunoglobulin, LBP, or LBP variant) can be accomplished using methods well known in the art. For example, the  
5 test polypeptide with and without the half-life enhancing molecule bound to it are injected into an animal model to determine the effects of the putative half-life enhancing molecule. If the half-life of the polypeptide with the molecule is enhanced relative to the half-life of the  
10 polypeptide without the molecule, then the molecule is a half-life enhancing molecule suitable for use in the RENPs of the invention. For example, a putative half-life enhancing amino acid sequence is incorporated into a fusion protein with BPI. Both native BPI and the  
15 BPI fusion protein are injected into mice. If the BPI fusion protein has a half-life significantly greater than the half-life of native BPI, then the amino acid sequence in the BPI fusion has half-life enhancing characteristics, and thus can be incorporated into the  
20 RENPs of the invention.

#### Vectors and constructs

Any nucleic acid vector can be used to express DNA encoding an RENP of the invention. The vectors containing the DNA sequence (or the corresponding RNA  
25 sequence) which may be used in accordance with the invention may be any prokaryotic or eukaryotic expression vector containing the DNA (e.g., cDNA) or the RNA sequence of interest. A variety of suitable vectors are publicly available and well known in the art. For  
30 example, a plasmid can be cleaved to provide linear DNA having ligatable termini. These termini are bound to exogenous DNA having complementary, like ligatable termini to provide a biologically functional recombinant

- 33 -

DNA molecule having an intact replicon and a desired phenotypic property.

A variety of techniques are available for DNA recombination in which adjoining ends of separate DNA fragments are tailored to facilitate ligation. The vector is constructed using known techniques to obtain a transformed cell capable of expression of the RENP. The transformed cell is obtained by contacting a target cell with a RNA- or DNA-containing formulation permitting transfer and uptake of the RNA or DNA into the target cell. Such formulations include, for example, plasmids, viruses, liposomal formulations, or plasmids complexed with polycationic substances such as poly-L-lysine or DEAC-dextran, and targeting ligands. Transformed cells containing a construct encoding an RENP of the invention are also known in the art as "host vector systems". Vectors for use in the construction of constructs encoding the RENPs of the invention, as well as methods for molecular cloning, nucleic acid manipulation, and transformation of both eukaryotic and prokaryotic host cells are well known in the art (see, for example, Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Ed., 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; hereby incorporated by reference with respect to bacterial and eukaryotic vectors, and methods and compositions for molecular cloning, nucleic acid manipulation, and transformation techniques).

The constructs of the invention may include promoter sequences to enhance expression of the RENP-encoding DNA, as well as other sequences (e.g., enhancers) which facilitate or enhance DNA expression. In addition, the RENP-encoding constructs can contain other components such as a marker (e.g., an antibiotic resistance gene (such as an ampicillin resistance gene) or  $\beta$ -galactosidase) to aid in selection of cells

- 34 -

containing and/or expressing the construct, an origin of replication for stable replication of the construct in a bacterial cell (preferably, a high copy number origin of replication), a nuclear localization signal, or other elements which facilitate production of the DNA construct, the protein encoded thereby, or both.

In general, the RENPs of the invention are constructed from a DNA sequence encoding BPI, a BPI variant, LBP, an LBP variant, as well as various half-life enhancing molecules known in the art such as immunoglobulin fragments. Both BPI and LBP have been cloned and their DNA and amino acid sequences determined (Figures 3A-3B and 4A-4B, respectively). The DNA and amino acid sequences of numerous immunoglobulins are known in the art. For example, the DNA sequence of IgG, IgG<sub>2a</sub>, and IgG<sub>4</sub> are suitable for use to enhance the half-life of the RENPs of the invention.

#### Expression of recombinant endotoxin-neutralizing polypeptides

Techniques for obtaining expression of exogenous DNA or RNA sequences in a host cell are known in the art (see, for example, Sambrook et al., *supra*; hereby incorporated by reference with respect to methods and compositions for eukaryotic and prokaryotic expression of a DNA encoding an RENP). Where the transformed cell is a prokaryotic host cell, the preferred host is *Escherichia coli*. Where the transformed cell is a eukaryotic host cell, preferably the host cell is a mammalian cell or a yeast cell. Preferably, the mammalian host cell is a Chinese Hamster Ovary (CHO) cell. Preferably, the yeast host cell is of the genus *Pichia*, more preferably a strain of *Pichia pastoris*.

For prokaryotic expression, the construct should contain at a minimum a bacterial origin of replication



- 35 -

and a bacterial promoter operably linked to the  
RENK-encoding DNA. For eukaryotic expression, the  
construct should contain at a minimum a eukaryotic  
promoter operably linked to a DNA of interest, which is  
5 in turn operably linked to a polyadenylation sequence.  
The polyadenylation signal sequence may be selected from  
any of a variety of polyadenylation signal sequences  
known in the art. Preferably, the polyadenylation signal  
sequence is the SV40 early polyadenylation signal  
10 sequence. The eukaryotic construct may also include one  
or more introns, which can increase levels of expression  
of the DNA of interest, particularly where the DNA of  
interest is a cDNA (e.g., contains no introns of the  
naturally-occurring sequence). Any of a variety of  
15 introns known in the art may be used. Preferably, the  
intron is the human  $\beta$ -globin intron and inserted in the  
construct at a position 5' to the DNA of interest.

#### Purification of RENPs

Purification of the RENPs of the invention can be  
20 performed according to any of a variety of protein  
purification techniques known in the art including gel  
electrophoresis, immunoprecipitation, ion exchange  
chromatography, affinity chromatography, or combinations  
thereof (see, for example, Guide to Protein Purification,  
25 Deutscher, ed., Academic Press, Inc., San Diego, CA,  
1990). Preferably, purification of RENPs is accomplished  
by a combination of column chromatographic techniques.  
For example, RENPs can be purified using a four-step  
purification procedure using 1) a cation exchange column  
30 (e.g., CM Sepharose), 2) an anion exchange column (e.g.,  
Fast Q Sepharose), 3) a second cation exchange column  
(e.g., CM Sepharose), and 4) a gel filtration sizing  
column (e.g., Sepharose CL6B).

- 36 -

Pharmaceutical compositions

The RENPs of the invention can be formulated as an active ingredient in a pharmaceutical composition. In general, the pharmaceutical composition contains a therapeutically effective amount of an RNP and a pharmaceutically acceptable carrier. The pharmaceutical composition can contain one or more RENPs. The amount of RNP which constitutes a therapeutically effective amount will vary according to the time of administration (e.g., therapeutic or prophylactic administration), the disease or condition to be treated, the route of administration, and various patient-dependent factors such as age, weight, gender, and severity of disease. Specific therapeutically effective amounts appropriate for administration are readily determined by one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th ed., Gennaro, ed., Mack Publishing Company, Easton, PA, 1990).

Pharmaceutically acceptable carriers suitable for use in the RNP-containing pharmaceutical compositions of the invention are well known to those skilled in the art. Selection of the pharmaceutically acceptable carrier will depend upon a variety of factors including the RNP to be administered, the route of administration, and the condition to be treated.

Pharmaceutically acceptable carriers suitable for use with the RENPs of the invention include, but are not limited to, 0.01-0.1 M and preferably 0.05 M succinate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Furthermore, pharmaceutically acceptable carriers may include detergents, phospholipids, fatty acids, or other lipid carriers. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive

- 37 -

11, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium  
5 chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.

Pharmaceutically acceptable carriers for use with the RENPs of the invention include lipid carriers. A lipid carrier is any lipid-soluble substance which  
10 inhibits protein precipitation and in which the proteins of the subject invention are soluble. Lipid carriers can be in the form of sterile solutions or gels, or can be detergents or detergent-containing biological surfactants. Examples of nonionic detergents include  
15 polysorbate 80 (also known as TWEEN 80 or polyoxyethylenesorbitan monooleate). Examples of ionic detergents include, but are not limited to, alkyltrimethylammonium bromide. Exemplary lipid carriers and methods for solubilizing BPI, and thus which can be  
20 used in pharmaceutical compositions containing an RENP of the invention, are described in USPN 5,234,912, incorporated herein by reference.

Where the pharmaceutically acceptable carrier is a lipid carrier, the lipid carrier may be a liposome. A  
25 liposome is any phospholipid membrane-bound vesicle capable of containing a desired substance, such as BPI or BPI variant, in its hydrophilic interior. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's  
30 dextrose, and the like. Preservatives, other pharmaceutically active compounds, and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

- 38 -

Disease conditions amenable to treatment with RENPs

Various disease conditions are amenable to treatment using the recombinant LPS-neutralizing proteins of the invention. In general, any condition of a mammalian subject (e.g., human, canine, feline, or bovine, preferably a human) which is associated with a toxic effect of endotoxin can be treated by administration of the RENPs of the invention.

Endotoxin-related disorders amenable to treatment include, but are not limited to, endotoxin-related shock, endotoxin-related disseminated intravascular coagulation, endotoxin-related anemia, endotoxin-related thrombocytopenia, endotoxin-related adult respiratory distress syndrome, endotoxin-related renal failure, endotoxin-related liver disease or hepatitis, systemic immune response syndrome (SIRS) resulting from Gram-negative infection, Gram-negative neonatal sepsis, Gram-negative meningitis, Gram-negative pneumonia, neutropenia and/or leucopenia resulting from Gram-negative infection, hemodynamic shock and endotoxin-related pyresis. Endotoxin-related pyresis is associated with certain medical procedures, such as, for example, trans-urethral resection of the prostate, and gingival surgery. The presence of endotoxin may result from infection at any site with a Gram-negative organism, or conditions which may cause ischemia of the gastrointestinal tract, such as hemorrhage, or surgical procedures requiring extracorporeal circulation. The important role of endotoxin in hemorrhage (with endogenous LPS translocation from the gut), trauma, and sepsis is well known. One skilled in the art can recognize additional conditions which can be treated using the therapy of the invention.

The recombinant, endotoxin-neutralizing proteins of the invention can also be administered to a patient

- 39 -

prophylactically, e.g. to a patient at risk of an endotoxin-related disorder. For example, the RENPs can be administered to a patient who has a Gram-negative infection and is at risk of bacteremia, but who has not yet exhibited symptoms associated with the toxic effects of endotoxin. The RENPs can also be administered prior to surgery where the risk of introduction of endotoxin into the patient is substantial. One of ordinary skill in the art can readily recognize other instances in which prophylactic administration of a RNP is appropriate. The conditions which identify an individual as being at risk of an endotoxin-related disorder are well known in the art.

#### Administration of RENPs

The recombinant, LPS-binding protein of the invention may be administered using various methods well known in the art. U.S. Pat. Nos. 5,171,739; 5,308,834; and 5,334,584; each incorporated herein by reference, describe methods and compositions for administration of BPI, and thus can provide additional guidance for administration of the RENPs of the invention. For example, the recombinant, LPS-binding protein can be administered by injection or inhalation. Administration by injection can be an intravenous, intramuscular, or subcutaneous route, or by direct injection directly into a site of infection (e.g., tissue or body cavity). Preferably, injection is intravenous. Administration by inhalation is accomplished by delivery of the RNP to the lungs via an aerosol delivery system or via direct instillation. The aerosol may be nebulized. Various devices and methods for aerosol drug delivery are well known in the art. Methods for determining the appropriate route of administration and dosage are generally determined on a case-by-case basis by the

- 40 -

attending physician. Such determinations are routine to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th ed., Gennaro, ed., Mack Publishing Company, Easton, PA, 1990).

5           Therapeutically effective amounts of an RENP can be determined according to methods well known to those skilled in the art. Specific dosages will vary according to a variety of factors, including the time of administration (e.g., therapeutic or prophylactic  
10 administration), the disease or condition to be treated, the route of administration, the RENP to be administered, and various patient-dependent factors such as age, weight, gender, and severity of disease. The specific dosage appropriate for administration is readily  
15 determined by one of ordinary skill in the art according to the factors discussed above (see, for example, Remington's Pharmaceutical Sciences, 18th ed., Gennaro, ed., Mack Publishing Company, Easton, PA, 1990). In addition, the estimates for appropriate dosages in humans  
20 may be extrapolated from determinations of the *in vitro* LPS binding affinity of the RENP used, the amount of the RENP effective to inhibit cytokine production by mononuclear cells *in vitro*, the amount of RENP effective to provide protection to LPS challenge, and/or various  
25 other *in vitro* and *in vivo* assays indicative of the biological activity of the RENP.

In general, the amount of RENP administered is an amount effective to bind LPS and thereby inhibit the undesirable biological activities associated with LPS  
30 including monocyte and neutrophil activation, TNF production, cytokine production, and other biological phenomena triggered by LPS in endotoxin-related disorders. Preferably, the amount of RENP administered is an amount effective to bind LPS and inhibit  
35 LPS-mediated stimulation of neutrophils and mononuclear cells.

- 41 -

In the rapid administration of the RENPs of the invention, an effective amount of an RENP is an amount effective to bind to LPS and thereby inhibit LPS-mediated stimulation of neutrophils and mononuclear cells in a subject having an endotoxin-related disorder. As used herein, "inhibit" means to inhibit at a level which is statistically significant and dose dependent. The terms "statistically significant" and "dose dependent" are well known to those skilled in the art. In general, an effective amount of an RENP in a pharmaceutical composition for treatment of a patient having an endotoxin-related disorder is an amount sufficient to deliver to the subject a recombinant protein of the subject invention at a concentration of between about 0.1 mg/kg of body weight and about 100 mg/kg of body weight, preferably between about 1 mg/kg of body weight and about 10 mg/kg of body weight. Preferably, the RENP(s) is administered by injection, infusion, or as an injected bolus so as to maintain a circulating RENP concentration of about 1-10  $\mu$ g/ml. The preferred circulating RENP concentration can vary according to a variety of factors, including the LPS binding affinity of the specific RENP(s) administered.

As used herein, a prophylactically effective amount of an RENP in a pharmaceutical composition for the prevention of an endotoxin-related disorder is an amount effective to bind LPS and prevent LPS-mediated biological activity, e.g., LPS-mediated stimulation of monocytes and neutrophils. In general, a prophylactically effective amount of an RENP is an amount of a composition effective to deliver between about 0.1 mg/kg of body weight and about 100 mg/kg of body weight, preferably between about 1 mg/kg of body weight and about 10 mg/kg of body weight, to the patient at risk of an endotoxin-related disorder.

- 42 -

The invention also provides an article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material. The packaging material includes a label which indicates that the pharmaceutical composition can be used for treating a subject suffering from an endotoxin-related disorder and/or for preventing an endotoxin-related disorder (e.g., inflammation) in a subject. The pharmaceutical composition contains a therapeutically effective and/or prophylactically effective amount of an RENP and a pharmaceutically acceptable carrier.

#### Assessment of therapy

The efficacy of the therapeutic or prophylactic use of the RENPs of the invention can be determined by monitoring patient symptoms associated with an endotoxin-related disorder. Such symptoms, and methods for monitoring, are well known in the art. For example, where the RENP is used in the treatment of a patient having an endotoxin-related disorder, the effectiveness of the RENP therapy can be assessed by monitoring fever, blood pressure, cytokine levels, and/or LPS levels in the patient's blood stream. The presence of LPS in the blood stream can be assayed as described above. Where the patient is not responding, it may be desirable to increase the dosage of the RENP pharmaceutical composition or, where the patient is not responding favorably, discontinue the RENP regimen.

#### Detectably-labeled RENPs

Various detectable labels, as well as methods of attachment of such labels to a protein, are well known in the art. Detectable labels can be any molecule recognized in the art as a means for identifying and/or



- 43 -

detecting a protein to which the detectable label is bound. Exemplary "detectable labels" include, but are not limited to radionucleotides, fluorescent moieties, biotin, and antigenic molecules (e.g., a polypeptide which can be specifically bound by an anti-polypeptide antibody). Thus, detectable labels include a portion of a chimeric protein (e.g., a fusion protein or genetically engineered protein) where a portion of the chimeric protein can be detected by, for example, binding of a detectably labeled antibody or other detectably labeled molecule which specifically binds the chimeric protein portion. For example, where the RENP contains a portion of the amino acid sequence of BPI, and an antibody which specifically binds that amino acid sequence of BPI in the context of the RENP is available, the BPI amino acid sequence is the detectable label.

Methods for attaching (e.g., covalently binding) a detectable label to a protein are well known in the art. For example, methods for preparation of  $^{125}\text{I}$ -labeled proteins, biotin-labeled proteins, and FITC-labeled proteins are well known. Methods for detectably labeling antibodies are also well known in the art. Methods for the production of antibodies for use in the subject invention (e.g., anti-BPI, anti-LBP, anti-BPI variant, anti-LBP variant, and anti-immunoglobulin fragment antibodies) are well known in the art (see, for example, Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988).

### 30 Detection of LPS in vitro

The detectably labeled RENPs of the invention can be used in various methods for the detection of LPS either *in vitro* or *in vivo*. Samples for which *in vitro* LPS detection is desirable include samples from a patient

- 44 -

suspected of having a Gram-negative infection, and samples from a product for use in a medical application (e.g., a recombinant protein solution where the protein was expressed in *E. coli*). Patient samples include  
5 samples of any body fluid, preferably blood or urine. Samples may be pre-treated prior to testing by, for example, concentrating the sample, or centrifugation to remove cells and cellular debris.

In general, *in vitro* detection of LPS in a sample  
10 suspected of containing LPS (test sample) is performed by contacting the test sample with an RENP of the invention for a time sufficient for the formation of RENP-LPS complexes, and the RENP-LPS complexes detected. The RENP-LPS complexes can be detected by virtue of a  
15 detectable label attached to the RENP, or by the binding of an anti-LPS antibody. Binding of the anti-LPS antibody can subsequently be detected by virtue of a detectable label bound to the antibody, or by the binding of a detectably labeled anti-anti-LPS antibody to the  
20 RENP-LPS-antibody complex.

The *in vitro* assay can be performed in solution by mixing the sample with a solution containing RENP, separation of RENP-LPS complexes (e.g., by immunoprecipitation), and detection of the RENP-LPS  
25 complexes formed, e.g., by virtue of a detectable label bound to the RENP. Alternatively, the *in vitro* assay is performed with RENP bound to a support, e.g., a polymeric substrate such as a microtiter well or a latex bead. Methods for binding proteins to a support are well known  
30 in the art. For example, an anti-RENP antibody can be bound to the support and the RENP subsequently bound to the support via binding to the anti-RENP antibody. After binding of the RENP to the support, the sample is then contacted with the support-bound RENP and any LPS in the  
35 sample allowed to bind to the RENP. Unbound material is

- 45 -

then washed away, and the RENP-LPS complex is detected by the binding of detectably labeled RENP or detectably labeled anti-LPS antibody.

The *in vitro* assay can also be performed as a competition binding assay. For example, a sample suspected of containing LPS (test sample) and a known amount of detectably labeled RENP are incubated together with a support having LPS bound to its surface. The test sample and the RENP may be preincubated prior to contact with the support-bound RENP. The level of detectably labeled RENP bound to the support in the test sample is compared to the level of detectably labeled RENP bound to the support in a negative control sample (detectably labeled RENP alone). A level of binding of detectably labeled RENP in the test sample which is lower than binding of detectably labeled RENP in the negative control sample is indicative of the presence of LPS in the sample.

In an alternative embodiment, the competition binding assay is performed with support-bound RENP. In this latter assay, detectably labeled LPS (e.g., radiolabeled LPS) is mixed with the test sample suspected of containing LPS, and the samples contacted with the support-bound RENP, and the amount of detectably labeled LPS bound to the support bound RENP detected. A level of detectably labeled LPS bound to the support in the test sample which is significantly lower than the amount of detectably labeled LPS in the negative control sample (radiolabeled LPS alone) is indicative of the presence of LPS in the test sample.

As is apparent from the description above, the *in vitro* LPS assays of the invention can be performed both qualitatively and quantitatively. For example, quantitative assays can be performed by comparing the results obtained with the test sample to results obtained

- 46 -

with parallel samples containing known amounts of LPS. Quantitative *in vitro* assays are indicative of, for example, the severity of Gram-negative infection in a patient sample from whom the sample was obtained, or a  
5 degree of contamination where the test sample is a fluid for administration to a patient (e.g., where the assay is performed as a step in quality control). One of ordinary skill in the art will appreciate upon reading the above-described *in vitro* assays that numerous variations  
10 of these assays can be performed without departing from the spirit or the scope of the invention.

#### Detection of LPS *in vivo*

Detectably labeled RENPs of the invention, preferably RENPs having an increased LPS binding affinity  
15 relative to LBP, can be used as a diagnostic to identify a site of Gram-negative bacterial infection in a patient. For example, a detectably labeled RENP is administered to a patient suspected of having a Gram-negative infection. Preferably, the detectable label is a radionucleotide  
20 such as  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{129}\text{I}$ ,  $^{131}\text{I}$ , or other beta-emitting radionuclide which can be readily detected with either a hand-held gamma radiation detection device or by nuclear medicine scan. Alternatively, the detectable label is a fluorescent molecule or other visually detectable label  
25 which can be visualized during, for example, endoscopy. Detection can be facilitated by increasing the ratio of detectable label to RENP.

The detectably labeled RENP is administered to the patient in an amount sufficient for binding of the RENP  
30 to the suspected infection site and detection of the detectable label. The detectably labeled RENP can be administered by injection, preferably by either intravenous injection or by direct injection into the body cavity or tissue suspected of containing the

- 47 -

infection site. In general, the amount of detectably labeled RENP administered will vary with according to numerous variables including the RENP and detectable label used, the location of the suspected site of infection, the route of administration, and various patient factors including size, weight, age, and suspected severity of the disease.

After administration, the detectably labeled RENP is allowed to circulate to reach the site of infection and/or incubate over the suspected site of infection. Bound detectably labeled RENP is detected using methods appropriate for the label used. For example, where the detectable label is a radionucleotide, bound RENP is detected using a radiation detecting device. Using this method, the site and the extent of a Gram-negative infection can be determined. Where desirable, the detectably labeled RENPs can be used to label a site or sites of infection which can then be imaged using any of a variety of imaging techniques known in the art (e.g., X-ray, CAT scan, MRI, or PET scan).

#### LPS decontamination using RENPs

The RENPs of the invention can also be used in the decontamination of a product prior to its medical application. For example, where a recombinant protein has been produced by expression in *E. coli*, a solution containing the recombinant protein can be applied to a support having bound RENP (e.g., an affinity column). LPS in the solution binds to the RENP bound to the support, and the LPS-free solution is collected. If necessary, the decontamination step can be repeated multiple times until an acceptably low amount of LPS (e.g. 0 to 0.001 ng/ml) is detected in the solution. Such decontamination procedures using the RENPs of the

- 48 -

invention can be used as a final step in quality control of, for example, recombinantly produced pharmaceuticals.

#### EXAMPLES

The following examples are put forth so as to  
5 provide those of ordinary skill in the art with a complete disclosure and description of how to carry out the invention and is not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers  
10 used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at  
15 or near atmospheric.

#### Example 1: Construction of RENPs

Specific examples of RENPs are described in Table 3, and are additionally designated by a construct name (e.g., NCY103) or lot number of the protein stock.

- 49 -

**Table 3****Examples of RENPs**

	SEQUENCE	CONSTRUCT NAME OR LOT #	DESCRIPTION
5	BPI	NCY101	Native sequence
	L <sub>1-197</sub> (I43->V)B <sub>200-456</sub> (N308->D)	NCY103	LBP-BPI chimera
	B <sub>1-199</sub> L <sub>200-456</sub>	NCY104	BPI-LBP chimera
	B(S351->A)	NCY105	Glycosylation site deleted
10	B(DS200->DP)	NCY106	Formic acid cleavage site inserted
	L <sub>1-199</sub> B <sub>200-456</sub> (S351->A)	NCY107	LBP-BPI chimera with glycosylation site deleted
	B <sub>1-199</sub>	NCY108	N-terminal domain of BPI
	B(1-190)	Lot #159699	N-terminal BPI fragment
	B(1-236)	Lot #159695	N-terminal BPI fragment
15	B(1-212)	Lot #159693	N-terminal BPI fragment
	B <sub>1-199</sub> Fc	NCY110	N-terminal BPI-IgG chimera
	B <sub>200-456</sub>	NCY112	C-terminal fragment of BPI
	L <sub>1-59</sub> B <sub>60-456</sub>	NCY114	LBP-BPI chimera
	L <sub>1-134</sub> B <sub>135-456</sub>	NCY115	LBP-BPI chimera
20	L <sub>1-276</sub> B <sub>278-456</sub>	NCY116	LBP-BPI chimera
	L <sub>1-359</sub> B <sub>360-456</sub>	NCY117	LBP-BPI chimera
	L(1-164)B(200-456)	Lot #164325	LBP-BPI chimera
	L(1-175)B(200-456)	Lot #164326	LBP-BPI chimera
	L <sub>1-197</sub> B <sub>200-456</sub>	NCY118	LBP-BPI chimera
25	B(F81->C)	NCY119	Cysteine insertion
	B(C132->A)	NCY120	Cysteine substitution

- 50 -

	B <sub>(C132→S)</sub>	NCY121	Cysteine substitution
	B <sub>(C135→S)</sub>	NCY122	Cysteine substitution
	B <sub>(C175→S)</sub>	NCY123	Cysteine substitution
<b>Table 3 (continued)</b>			
5	SEQUENCE	CONSTRUCT NAME OR LOT #	DESCRIPTION
	B <sub>(C132→A)(C135→S)(C175→S)</sub>	NCY124	Multiple cysteine substitution
	B <sub>(1-132→A)(C135→S)(C175→S)</sub>	NCY125	Multiple cysteine substitution
	L <sub>(1-134)</sub> B <sub>(136-361)</sub> L <sub>(360-456)</sub>	NCY133	LBP-BPI chimera
	L <sub>(1-134)</sub> B <sub>(136-275)</sub> L <sub>(274-456)</sub>	NCY134	LBP-BPI chimera
10	L <sub>(1-198)</sub> B <sub>(202-275)</sub> L <sub>(274-456)</sub>	NCY135	LBP-BPI chimera
	L <sub>(1-198)</sub> B <sub>(202-361)</sub> L <sub>(360-456)</sub>	NCY136	LBP-BPI chimera
	B <sub>(1-41)</sub> L <sub>(42-199)</sub> B <sub>(200-456)</sub>	Lot #162303	BPI-LBP-BPI chimera
	B <sub>(1-190)(C173→A)</sub>	Lot #162305	N-terminal BPI fragment with cationic substitution
15	B <sub>(K27→S)(K30→L)(K33→T)(K42→R)(K44→P)(K48→R)(R59→H)(B<sub>CAT7</sub>)</sub>	NCY137	Cationic Substit. (7)
20	B <sub>(K77→S)(K86→R)(K90→R)(R96→S)(K118→L)(K127→R)(B<sub>CAT6</sub>)</sub>	NCY138	Cationic Substit. (6)
	B <sub>(K148→G)(K160→D)(K160→N)(K161→Q)(R167→Q)(K169→V)(K177→M)(K185→D)(K198→E)(B<sub>CAT9</sub>)</sub>	NCY139	Cationic Substit. (9)
25	B <sub>(K77→S)(K86→R)(K90→R)(R96→S)(K118→L)(K127→R)(K148→G)(K160→D)(K160→N)(K161→Q)(R167→Q)(K169→V)(K177→M)(K185→D)(K198→E)(B<sub>CAT15</sub>)</sub>	NCY140	Cationic Substit. (15)
30	L <sub>(S77→K)(R86→K)(R90→K)(S96→K)(L118→K)(R126→K)(L<sub>CAT6</sub>)</sub>	NCY141	Cationic Repl. (6)



- 51 -

	L(G147->K)(D148->K)(N158->K) (Q159->K)(Q165->R)(V167->K)(M 175->K)(D183->K)(E198->K) (L <sub>CAT9</sub> )	NCY142	Cationic Repl.(9)
5	L(S77->K)(R88->K)(R90- K)(S98->K) (L118->K)(R126->K)(G147->K)(D 148->K)(N158->K)(Q159->K)(Q16 5->R)(V167->K)(M175->K)(D183- >K)(E198->K) (L <sub>CAT15</sub> )	NCY143	Cationic Repl. (15)
10	L <sub>(1-198)</sub> <sup>B</sup> (201-456) <sup>PC</sup>	NCY144	LBP-BPI-IgG chimera

- 52 -

Table 3 (continued)		
LBP	NCY102	native sequence
L <sub>1-199</sub>	NCY109	N-terminal LBP fragment
L <sub>1-199</sub> <sup>Fc</sup>	NCY111	LBP-Ig chimera
L <sub>200-458</sub>	NCY113	C-terminal LBP fragment
L <sub>(A132→C)</sub>	NCY126	Cysteine insertion
L <sub>(C81→F)</sub>	NCY127	Cysteine substitution
L <sub>(C81→S)</sub>	NCY128	Cysteine substitution
L <sub>(C135→S)</sub>	NCY129	Cysteine substitution
L <sub>(175→S)</sub>	NCY130	Cysteine substitution
L <sub>(C81→F)(C135→S)(C175→S)</sub>	NCY131	Multiple cysteine substitution
L <sub>(C81→S)(C135→S)(C175→S)</sub>	NCY132	Multiple cysteine substitution

The proteins encoded by the LBP and L<sub>1-359</sub>B<sub>360-456</sub> constructs facilitated the LPS-mediated cellular response, indicating that LBP amino acid residues 275-359 are required for this LBP activity.

The cDNA sequences of BPI and LBP are shown in Figures 3A-3D and 4A-C, respectively, with each nucleotide designated numerically. DNA encoding the RENPs can be prepared using a variety of techniques well known in the art, including protein fusion techniques, site-directed mutagenesis, and PCR (see, for example, Sambrook et al., *supra*; Zoller, M.J., et al., *Methods Enzymol.* 154:329 (1987)). For example, in the construction of the RENP L<sub>1-197</sub>B<sub>200-456</sub>, the sequence "ATAGAT<sub>723</sub>" and "ATTGAC<sub>700</sub>" was chosen as a convenient sit to insert a ClaI restriction site (ATCGAT) by which to combine portions of both BPI (former) and LBP (latter). Oligonucleotide primers were designed which overlap this region but contain the ClaI sequence, and

- 53 -

were synthesized on an ABI 380B synthesizer (Applied Biosystems Inc., Foster City, CA). Additional primers were designed to bind to the 5' and 3'- ends of both molecules, which primers contained NheI (5') and XhoI (3') restriction sites for insertion into the vector. These primers were used to amplify portions of the cDNA molecules encoding amino acid residues 1-199 (A) and 200-456 (B) of LBP and BPI by cyclic DNA amplification. The resulting DNA fragments were digested with the appropriate restriction enzymes and then purified by gel electrophoresis.

#### Example 2: Mammalian Expression

In order to produce BPI, LBP, or RENPs of the invention in mammalian cells, the cDNA sequences were inserted into a suitable plasmid vector. A suitable vector for such an application is pSE, which contains the origin of replication and early and late promoters of SV40, followed by multiple insert cloning sites, followed by the termination sequences from the hepatitis B surface antigen gene. An origin of bacterial DNA replication, and the genes encoding ampicillin resistance and dihydrofolate reductase were also included in the plasmid for production of large amounts of DNA using bacterial host cells. Similar vectors have been used to express other foreign genes (Simonsen et al., *Biologicals* 22:85 (1994)). Another suitable vector, particularly for rapidly obtaining small quantities of RENPs was pCIP4 (Invitrogen Corp., San Diego, California). pCEP4 contains a CMV promoter, followed by multiple insert cloning sites, followed by SV40 termination sequences. Also contained within the plasmid are an origin of bacterial DNA replication, and the genes encoding resistance to ampicillin and hygromycin B. With pCEP4 and pSE, the same insert cloning sites as pSE for easy

- 54 -

insert shuttling between the vectors were used. Once introduced into mammalian cell hosts, this specialized plasmid replicates as an episome, allowing semistable amplification of introduced DNA sequences. The high gene  
5 copy number is maintained through the selective pressure of culture in the presence of hygromycin B.

A second expression system (EBV/293) was used to rapidly obtain small quantities of recombinant proteins of the subject invention when useful. This system was  
10 constructed to use the same insert cloning sites as pSE for easy insert shuttling, but utilized the Epstein-Barr virus promoter (EBV) to drive heterologous expression (pCEP4). Once introduced into mammalian cell hosts, this specialized plasmid replicates as an episome, allowing  
15 semistable amplification of introduced DNA sequences. The high gene copy number is maintained through the selective pressure of culture in the presence of hygromycin plus G418. Similar expression systems are commercially available (e.g., Invitrogen, Inc., San  
20 Diego, CA).

Vector DNA was prepared for acceptance of BPI cDNA by digestion with Nhe I and Xho I, and was subsequently dephosphorylated by treatment with alkaline phosphatase. The prepared fragments encoding BPI, LBP, or an RENP were  
25 ligated into pSE or pCEP4, and the resulting recombinant colonies were screened by agarose gel electrophoresis. Subsequently, the DNA sequences were confirmed by standard enzymatic sequencing methods (e.g., Sanger, 1974).

30 Expression plasmid DNA purified by either CsCl gradients with Plasmid or Midi Kits (Qiagen, Chatsworth, California) was used to transform Chinese hamster ovary strain DUXB11 (pSE) and 293-EBNA cells (Invitrogen Corp., San Diego, California) (pCEP4). Transfection was  
35 performed using lipofectin (Bethesda, Research Labs,

- 55 -

Gaithersberg, MD) by standard methods. The resulting transformed cells were selected in GHT minus medium (DUKXB11s) or in REM and 10% calf serum (293s). For the DUKXB11s, clones were selected and were passed through sequential rounds of culture in increasing concentrations of methotrexate in order to amplify the DHFR gene and associated heterologous genes. Supernatants from transfected cells, either mixed populations or clones derived from the mixed population, were assayed for RENPs by ELISA using antibodies specific for BPI, LBP, or immunoglobulin as appropriate.

### Example 3: Yeast Expression

BPI and L<sub>1-197</sub>B<sub>200-456</sub> were successfully expressed in the methylotrophic yeast *Pichia pastoris*. *Pichia* was chosen as a suitable expression system for BPI and RENPs due to its lack of LPS (endotoxin to which BPI and RENPs bind) and its ability to produce high levels of mammalian proteins.

*Pichia pastoris* strain GS115 (Invitrogen, San Diego, California) was transformed with plasmids encoding BPI and L<sub>1-197</sub>B<sub>200-456</sub>, and transformed colonies were selected according to the procedures outlined by Invitrogen (A Manual of Methods for Expression of Recombinant Proteins in *Pichia pastoris*, Version 1.5, Invitrogen, San Diego, California). For both BPI and L<sub>1-197</sub>B<sub>200-456</sub>, protein was secreted into the medium in a small-scale batch fermentation run. 116 ng/ml were secreted for the one BPI construct assayed, and 14, 11, and 10 ng/ml were secreted for the three constructs L<sub>1-197</sub>B<sub>200-456</sub> constructs assayed. Secretion was assayed by enzyme-linked immunosorbant analysis (ELISA). The majority of protein for both constructs was not secreted, as shown by Western blot analysis with a polyclonal anti-BPI antibody (INVN 1-2) (prepared by conventional

- 56 -

techniques by injecting rabbit with BPI) and alkaline phosphatase-conjugated goat anti-rabbit antibody. The Western blot is shown in Figure 18.

Purified BPI from Chinese Hamster ovary cells (CHOs) was used as a positive control (lane 12). In lane 1 a sample from untransformed GS115 cells served as a negative control. The antibodies did not recognize any proteins from the untransformed GS115 cells. The next three lanes (2-4) were samples from colonies transformed with the construct for BPI and the last 6 lanes (5-10) were samples from colonies transformed with the construct for L<sub>1-197</sub>B<sub>200-456</sub>. The amount of intracellular BPI or L<sub>1-197</sub>B<sub>200-456</sub> expressed in the batch fermentation run, based on the amount of standard BPI loaded, was roughly 100 µg/ml of medium for the BPI and L<sub>1-197</sub>B<sub>200-456</sub> colonies.

#### Example 4: Protein Purification

BPI was purified from conditioned media using the following four-step purification. BPI was captured on CM Sepharose (Pharmacia LKB Biotechnology). The column was washed in 50 mM Tris pH 7.4, and protein was eluted with 50mM Tris buffer pH 7.4 + 1 M NaCl. The eluate was diluted 10X with 50mM Tris pH 8.5, run over Fast Q Sepharose, and the flow-through was collected. BPI was re-captured on CM Sepharose and again eluted as before. Buffer exchange into 10 mM Succinate + 110 mM NaCl pH 6 was performed using Sepharose CL6B (Pharmacia LKB Biotechnology). Finally, Tween 20 was added to the formulated material to a final concentration of 0.05%.

LBP (NCY102) was captured from cell culture medium on Fast S Sepharose (Pharmacia). The column was washed with 50 mM Tris pH 7.4, and protein was eluted using 50mM Tris pH 7.4 + 1 M NaCl. The eluate was diluted 10X in 50mM Tris pH 8.5 and run over HiLoad Q Sepharose

- 57 -

(Pharmacia). Protein was eluted with a 0-1 M NaCl gradient in 50mM Tris pH 8.5. Appropriate fractions were pooled according to migration on SDS PAGE electrophoresis. LBP concentration was diluted to 4.0 mg/ml, and the pH was adjusted to 7.0 with 100 mM HCl.

L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) was purified from cell culture medium using the same method described for LBP.

B<sub>1-199</sub>L<sub>200-456</sub> and B<sub>(S351->A)</sub> were purified using the same protocol as for BPI, except that the size exclusion step was omitted.

L<sub>1-59</sub>B<sub>60-456</sub>, L<sub>1-134</sub>B<sub>135-456</sub> and B<sub>CAT6</sub> were captured on a Poros II HS cation exchange column (PerSeptive Biosystems, Cambridge, MA) at pH 7.4. The column was washed with 20 mM HEPES buffer at pH 7.5, and eluted with 20 mM HEPES pH 7.5 with 1 M NaCl. The eluate was diluted 5X in 20 mM HEPES pH 7.5 and applied to a Poros HQ anion exchange column (PerSeptive) with the flow-through applied directly to a POROS II HS column. The POROS II HS column was eluted with 3.3 mM acetate, 3.3mM MES and 3.3 mM HEPES, pH 6.0 with a 0-1 M NaCl gradient.

L<sub>1-359</sub>B<sub>360-456</sub> and L<sub>(1-198)</sub>B<sub>(201-456)</sub>Fc were captured from conditioned medium at pH 7.4 on a Poros II HS column. The column was washed with 20mM HEPES buffer at pH 7.5, and eluted with 20mM HEPES pH 7.5 + 1 M NaCl. The eluate was diluted 10X with 20mM HEPES pH 7.5, loaded on a second, smaller Poros II HS column, and eluted with 3.3 mM acetate, 3.3 mM MES and 3.3 mM HEPES, pH 6 with a 0-1 M NaCl gradient.

#### Example 5: BPI Activity Against N. meningitidis and N. gonorrhoeae

BPI suppresses TNF release by human inflammatory cells in response to lipopolysaccharide (LPS) derived from a wide range of Gram-negative bacterial species. In order to test the activity of BPI against Gram-negative

- 58 -

lipooligosaccharide (LOS) from the pathogenic bacteria Neisseria meningitidis and N. gonorrhoeae, non-viable bacteria were pre-treated with recombinant BPI and incubated with human whole blood for 4 hours at 37°C.

- 5 Without BPI, N. meningitidis at 10<sup>5</sup> bacteria/ml stimulated the release of  $2.93 \pm 0.53$  ng/ml of TNF, while N. gonorrhoeae was a more potent stimulator of TNF release: 10<sup>4</sup> bacteria/ml induced  $8.23 \pm 0.32$  ng/ml of TNF. In both cases, 10 µg/ml BPI completely inhibited
- 10 TNF release. This indicates that BPI is able to bind and detoxify LOS of these organisms, as well as bind LPS. Thus, BPI can be useful as a therapeutic agent against LOS-mediated tissue damage associated with these pathogenic Neisseria species.

15 Example 6: biotinylated BPI Binding Competition Assays

- Competition assays for binding of LPS immobilized on microtiter plates was performed using a modified procedure described by Tobias et al., *J. Biol. Chem.* 264:10867 (1989). Briefly, Immulon 3 microtiter plates
- 20 (96-well, Dynatech Biotechnology Products, Chantilly, VA) were coated with 1 or 4 µg of S. minnesota R595 Re LPS (LIST Biological Labs, Inc., #304) in 50mM borate pH 9.5-9.8 + 20-25 mM EDTA overnight at 37°C. Blank, non-LPS coated wells were included on each plate and
- 25 binding to these wells was used to determine non-specific binding. Absorbance values from wells which were not pre-coated with LPS consistently gave optical density readings of less than 0.05. Plates were then washed extensively under running distilled deionized water, then
- 30 dried at 37°C. Assay wells were blocked for 60 minutes at 37°C with 1-2% very low endotoxin BSA (Sigma, St. Louis, MO) prepared in pyrogen-free Tris-buffered saline (50mM Tris pH 7.4 + 150 mM NaCl). The wells were emptied, and biotinylated BPI was incubated in the



- 59 -

presenc or absence of unlabeled BPI or recombinant protein of the subject invention diluted in assay buffer (pyrogen-free TBS + 1 mg/ml low endotoxin BSA, and 0.05% Tween-20) was incubated in the LPS coated and uncoated  
 5 wells for 2-3 hours at 37°C in a total volume of 100 µl/well. After four washes in assay buffer, plates were developed with streptavidin conjugated to alkaline phosphatase (BioRad, Burlingame, California) followed by 100 µl of PNP substrate solution (Sigma) freshly prepared  
 10 from two 5 mg tablets dissolved in 10 ml substrate buffer. Substrate buffer is prepared with 24.5 mg MgCl<sub>2</sub>, 48 ml diethanolamine, brought up to 400 ml, pH adjusted to 9.8 and volume brought up to 500 ml. Absorbances were read at 405 nm on a Vmax kinetic microplate reader  
 15 (Molecular Devices, Inc., Menlo Park, CA).

The relative LPS binding affinities of BPI, LBP and RENPs were tested in the competitive binding assay described above using 10 ng/ml biotinylated BPI. In these experiments, BPI inhibited biotinylated BPI binding to LPS  
 20 in a concentration-dependent manner (Figure 7). Modest inhibition of biotinylated BPI-binding was observed using NCY102 (LBP) and L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub>, suggesting that BPI has either a higher affinity for LPS bound to a surface or that LBP and L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> bind  
 25 to a different site on LPS. B<sub>1-199</sub>L<sub>200-456</sub>, which contains the N-terminal domain of BPI, competed with biotinylated BPI at similar concentrations as unlabeled BPI, suggesting a similar affinity and binding site.

Competition between either L<sub>1-197</sub>B<sub>200-456</sub> (NCY118)  
 30 or L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> (NCY103) with biotinylated BPI occurred at similar concentrations, giving overlapping curves (Figure 13A) indicating that the two amino acid differences between these two molecules  
 [L<sub>1-197</sub>B<sub>200-456</sub>->L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub>: (I43->V) and  
 35 (N206->D)] had no effect on affinity for immobilized LPS.

- 60 -

- L<sub>(1-198)</sub>B<sub>(201-456)</sub>Fc (an IgG chimera consisting of L<sub>1-197</sub>B<sub>200-456</sub> linked to human IgG1 Fc constant region of the immunoglobulin molecule) does not have an altered ability to compete with biotinylated BPI (Figure 13A).
- 5 L<sub>1-59</sub>B<sub>60-456</sub> and L<sub>1-134</sub>B<sub>135-456</sub> showed a similar affinity for LPS which affinity was very similar to that observed for BPI, suggesting that the region between amino acid residues 1-59 (or 1-134) probably plays a minimal role in LPS binding (Figure 13B). Together with data showing the
- 10 B<sub>1-199</sub>L<sub>200-456</sub> competes effectively with BPI (Figure 7), these results indicate that amino acid residues 134-199 are important structural components of the high-affinity LPS-binding domain of BPI.

The importance of the region between amino acid residues 134 to 197 in LPS affinity was further demonstrated by the markedly reduced affinity of B<sub>CAT9</sub>, a mutant in which all of the cationic amino acids of the BPI molecule (particularly the cationic residues of BPI amino acids 134-200) are replaced with the corresponding amino acid residues found in LBP. These changes resulted in a molecule with binding affinity for LPS which was more similar to that of LBP than BPI (Figure 13C, and Figure 7). Amino acid residues 360 to 456 of BPI are apparently not involved in LPS binding as demonstrated by

20 the relative inability of L<sub>1-359</sub>B<sub>360-456</sub> to displace biotinylated BPI from LPS (Figure 13C). The apparent binding affinity of L<sub>1-359</sub>B<sub>360-456</sub> for LPS is similar to that of LBP and B<sub>CAT9</sub>, which affinity is approximately two orders of magnitude lower than the apparent affinity of

25 BPI for LPS.

Thus, the domain of BPI which participates in binding to immobilized LPS is localized in the N-terminal half of the BPI molecule, since B<sub>1-199</sub>L<sub>200-456</sub> has the greatest ability to displace native BPI from LPS coated onto microtiter plates. This domain of BPI has been more

35

- 61 -

specifically localized to a region between amino acid residues 134-199.

Example 7: Chromogenic LAL Assay

To test the relative abilities of BPI, LBP and  
5 RENPs to neutralize LPS *in vitro*, these proteins were  
tested for inhibitory activity in the chromogenic LAL  
assay. Briefly, BPI and RENPs (25  $\mu$ l of 0-200  $\mu$ g/ml)  
were pre-incubated for 1 hour at 37°C with 1 EU/ml of *E.*  
*coli* 0111:B4 LPS, (Whitaker Biologicals, Walkersville,  
10 MD). The mixtures were then tested for LAL activity  
using the chromogenic LAL assay kit (Whitaker  
Biologicals, Walkersville, MD). The results are shown in  
Figure 8 and Table 4. LPS was neutralized by the various  
proteins tested in the order of:

15  $B_{(S351 \rightarrow A)} \geq BPI > L_{1-197(I43 \rightarrow V)} B_{200-456(N206 \rightarrow D)} >$   
 $B_{1-199} L_{200-456} > LBP$ . Several studies were carried out  
with different lots of each protein and the  $IC_{50}$  values  
were determined. The averaged  $IC_{50}$  values are shown in  
Table 4.

- 62 -

Table 4LPS Inhibition in the Chromogenic LAL Assay

5 Product	IC <sub>50</sub> ( $\mu$ g/ml)	No. of test
<hr/>		
B <sub>(S351-&gt;A)</sub>	1.5	(n=1)
10 BPI	5.2 $\pm$ 3.3	(n=10)
L <sub>1-197(I43-&gt;V)</sub> B <sub>200-456(N206-&gt;D)</sub>	28.0 $\pm$ 20.0	(n=4)
B <sub>1-199</sub> L <sub>200-456</sub>	40.0	(n=1)
LBP	65.0 $\pm$ 31.0	(n=4)

15

These results demonstrate that BPI neutralizes LPS activity in the LAL assay at lower concentrations than LBP. B<sub>1-199</sub>L<sub>200-456</sub>, which contains the N-terminal domain of BPI, effectively competes with BPI for binding to LPS (see Figure 7) but is a relatively poor inhibitor of LPS in the LAL assay. These results indicate that the N-terminal (LPS-binding) domain of BPI alone does not account for the neutralizing activity of BPI in the LAL assay. L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> was a more potent inhibitor than LBP or B<sub>1-199</sub>L<sub>200-456</sub>, suggesting that the C-terminal domain of BPI plays a very important role in endotoxin neutralization in the LAL assay.

Additional results of LPS neutralizing activity in the chromogenic LAL assay are shown in Table 5.

30 L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub>, L<sub>1-59</sub>B<sub>60-456</sub>, and L<sub>1-134</sub>B<sub>135-456</sub> share the C-terminal half of the BPI molecule, again indicating that this domain plays an important role in LPS-neutralizing activity. Also, these data indicate that the 199-456 region is most important in LPS

- 63 -

neutralization since adding BPI amino acid residues  
between 136-456 or 60-456 did not improve LPS  
neutralizing activity. Together with the LPS binding  
data, these results further indicate that the C-terminal  
5 half of BPI is important for neutralization, while the  
N-terminal sequence is more critical for LPS binding.

- 64 -

Table 5LPS Inhibition in the Chromogenic LAL Assay

5	Protein		IC50	n
	BPI	Cumulative	1.58 ± 1.58	94
		Lot# 149718	1.57 ± 1.01	54
		Lot# 149719	1.69 ± 0.35	7
		Lot# 149722	1.70 ± 0.28	2
10		Lot# 149724	1.41 ± 0.45	45
		Lot# 155794	1.95 ± 0.92	2
	LBP	Cumulative	55.92 ± 30.53	8
		Lot# 151281	34.33 ± 7.45	6
		Lot# 151204	77.50 ± 24.45	2
15	L <sub>1</sub> -197(I43->V)B <sub>200-456</sub> (N206->D) 22.86 ± 16.28	54 Cumulative		
		Lot# 151235	25.50 ± 0.71	2
		Lot# 151242	36.50 ± 2.12	2
		Lot# 151274	3.46 ± 2.18	38
20		Lot# 159616	8.83 ± 4.91	4
	B <sub>1</sub> -199L <sub>200-456</sub>	Cumulative	24.19 ± 6.42	9
		Lot# 151246	12.50 ± 0.26	3
		Lot# 152658	10.70	1
		Lot# 155737	40.18 ± 34.48	4
25	B <sub>1</sub> -199	Cumulative	5.52 ± 5.05	17
		Lot# 151285	1.12 ± 0.00	2
		Lot# 155709	9.73 ± 1.18	3
		Lot# 155779	2.13 ± 0.81	2
	L <sub>1</sub> -59B <sub>60-456</sub>	Lot# 155754	3.64 ± 1.64	5
30	L <sub>1</sub> -134B <sub>135-456</sub>	Lot# 155756	5.02 ± 3.11	5
	L <sub>1</sub> -275B <sub>278-456</sub>	Lot# 155791	14.00 ± 2.65	3
	L <sub>1</sub> -359B <sub>360-456</sub>	Lot# 155733	>100	4

- 65 -

<u>Protein</u>		<u>IC50</u>	<u>n</u>
L <sub>1-197</sub> B <sub>200-456</sub>	Cumulative	12.75 ± 3.54	12
	Lot# 155758	10.25 ± 30.9	8
	Lot# 159619	15.25 ± 5.91	4
5 B <sub>CAT6</sub>	Lot# 155785	1.97 ± 0.06	3
B <sub>CAT9</sub>	Lot# 155762	29.60 ± 23.23	5
B <sub>CAT15</sub>	Lot# 155788	7.87 ± 2.80	3
L <sub>(1-198)</sub> B <sub>(202-275)</sub> L <sub>(274-456)</sub> >100 <sub>3</sub>		Lot# 159649	
10 L <sub>(1-198)</sub> B <sub>(201-456)</sub> FC	Lot# 155760	12.15 ± 6.00	4
L <sub>1-199</sub>		9.2	1
B <sub>1-199</sub>		10.1 ± 0.92	5
L <sub>(1-134)</sub> B <sub>(136-275)</sub> L <sub>(274-456)</sub> 22.00 ± 15.25 <sub>4</sub>		Lot# 159643	

15

B<sub>CAT9</sub>, which contains the entire BPI sequence except for nine cationic residues between positions 148 and 197 showed very poor LPS-neutralizing activity, suggesting that these residues are important in LPS-neutralizing activity. Similarly, this compound was relatively ineffective at competing with native BPI for binding to LPS. These cationic residues may permit correct structural conformation of the molecule, since both L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> and B<sub>CAT9</sub> contain the C-terminal domain of BPI, yet L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> has potent neutralizing activity while B<sub>CAT9</sub> does not.

#### Example 8: Inhibition of FITC-labeled LPS binding to human monocytes

30 The relative LPS-binding affinities of RENPs of the invention were investigated by examining the abilities of the RENPs to inhibit LPS binding to human

- 66 -

peripheral blood monocytes. Blood collected in acid citrate dextrose-containing VACUTAINER<sup>TM</sup> tubes (Becton Dickinson, Rutherford, NJ) was diluted 1:4 in Hank's balanced salt solution (HBSS) minus calcium and magnesium  
5 (Gibco BRL, Grand Island, MD). Mononuclear cells were isolated using Ficol-Paque (Pharmacia Inc., Piscataway, NJ). Cells were washed three times in HBSS, then brought up to an appropriate volume of RPMI 1640 with glutamine and antibiotics to give approximately  $1 \times 10^6$  cells/ml.  
10 To one ml aliquots of cells, FITC-LPS was added to a final concentration of 500 ng/ml. Tubes were closed and incubated at 37°C on a rocking platform. At the end of the incubation, cells were washed twice with PBS with 0.05% Human Serum Albumin and 0.02% sodium azide. FACS  
15 analysis of the cells was performed on a FACStar flow cytometer, Immunocytometry System, Becton Dickinson (Mountain View, CA). The monocyte portion of the cell population was determined by side scatter versus forward scatter gating and confirmed by staining a separate  
20 aliquot of cells with phycoerythrin-conjugated anti-DR antibody (Becton Dickinson Immunocytometry Systems, Milpitas, CA). Results are reported as logarithmic scale mean fluorescence intensity.

To determine the relative abilities of BPI or  
25  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  to inhibit LPS binding to human peripheral blood monocytes, isolated human peripheral blood mononuclear cells were incubated with 10% human serum containing 500 ng/ml FITC-conjugated E. coli 055:B5 LPS in the presence or absence of BPI or  
30  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$ . Binding of FITC-LPS to monocytes could be inhibited by increasing concentrations of both BPI and  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  (Figur 9). Thus  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  has BPI-like activity, despite the fact that  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  contains  
35 the N-terminal domain of LBP. These data, along with the



- 67 -

results of the LPS neutralization studies shown in Figure 8, suggest that the C-terminal domains of BPI and LBP, and not the N-terminal domains, determine whether the proteins inhibit or mediate LPS activation of cells.

- 5 Further studies were undertaken to determine the effects of BPI, LBP, L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> and B<sub>1-199</sub>L<sub>200-456</sub> on FITC-labeled LPS binding to peripheral blood monocytes in the presence and absence of serum. In a serum-free FITC-labeled LPS binding system where no LBP is available, FITC-labeled LPS does not bind to cells. In contrast recombinant LBP facilitated LPS binding to cells at concentrations as low as 100 ng/ml. B<sub>1-199</sub>L<sub>200-456</sub> also facilitated binding, although to a lesser extent. Neither BPI or L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> promoted significant binding of LPS to cells. These data indicate that the C-terminal domain of LBP is active in LPS binding to cells. The N-terminal domain of BPI may exert an inhibitory influence on LPS binding to cells mediated by the C-terminal domain of LBP because
- 15 B<sub>1-199</sub>L<sub>200-456</sub> was less active than LBP.

- Normal human serum contains about 1-10 µg/ml LBP. In the presence of 10% autologous serum, BPI and L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> potently inhibited FITC LPS binding to monocytes, with BPI showing slightly greater
- 25 potency. B<sub>1-199</sub>L<sub>200-456</sub> had marginal activity, and LBP had no effect (Figure 14A). These data indicate the importance of the BPI C-terminus in this test of LPS neutralization. B<sub>1-199</sub>L<sub>200-456</sub>, which lacks the C-terminal domain of BPI, is approximately two orders of magnitude
- 30 less potent at blocking LPS binding. LBP, as expected, had no effect. Thus, BPI can intervene in the sepsis cascade by preventing LPS from binding to monocytes and causing release of TNFα.

- 68 -

Example 9: THP-1 Cell TNF Production Assay

THP-1 cells were obtained from the American Tissue Culture Collection (Rockville, MD) and were maintained in REM medium containing 10% fetal bovine serum, 2 mM L-glutamine, 100 units penicillin and 100 µg/ml streptomycin. Cells were passed at  $2 \times 10^5$  cells/ml every 3 days. Responsiveness of THP-1 cells to LPS was induced by culturing the cells for 48 hours in REM medium containing 10% fetal calf serum, 2 mM L-glutamine, 100 units penicillin, 100 µg/ml of streptomycin and 100 nM PMA at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Cells were cultured in 96-well flat-bottomed tissue culture plates at  $1-2 \times 10^5$  cells per well in a final volume of 200 µl. After 48 hours, adherent cells were washed three times with 200 µl of medium without serum. To 180 µl of medium without serum but with 0.5% HSA, LPS (10 µl at 200 ng/ml) and/or BPI, LBP or other RENPs were added (10 µl at 0-2 mg/ml) and the cells were cultured for an additional 4 hours. After 4 hours, supernatants were transferred to a U-bottomed 96 well plate and the plate was centrifuged (500 x g, 12 min) to pellet any cell debris. Supernatants were then stored in a second plate at -20°C until assayed for TNF by ELISA.

To further identify the regions of BPI which contribute to LPS-neutralizing activity, and the domains of LBP which are responsible for transducing the LPS signal to cells, the abilities of RENPs to replace LBP were compared under serum-free conditions. In these experiments, cells of the promonocytic cell line THP-1 were induced to respond to LPS by culturing for 48 hours with phorbol ester. After induction, cells were stimulated with 19 ng/ml of LPS in the presence or absence of the recombinant protein. In this system, TNF release requires a source of LBP. Data from these experiments (Figure 15) show that only LBP and

- 69 -

L<sub>1-359</sub>B<sub>360-456</sub> stimulated TNF release. Thus the domain of LBP responsible for facilitating LPS-induced TNF release is within amino acid residues 199-359. Interestingly, B<sub>1-199</sub>L<sub>200-456</sub> did not mediate TNF release in a serum-free system. This may indicate that the N-terminal domain of BPI binds too tightly to LPS to allow transfer of LPS to CD14 on the macrophage surface. Figure 16 shows an additional comparison of TNF production. Because L<sub>(1-198)</sub>B<sub>(202-275)</sub>L<sub>(274-456)</sub> includes LBP domain 274-456 and has activity, the active domain may comprise only residues 274-359.

#### Example 10: LPS-Induced TNF Release In Whole Blood

Peripheral blood from normal human volunteers was collected in heparin-containing VACUTAINER™ tubes (Becton Dickinson). To one milliliter of whole blood, BPI, a protein of the subject invention, or buffer control was added, followed by 1 ng/ml *E. coli* 055:B5 refined standard endotoxin (RSE) (Whitaker Bioproducts). Samples were incubated in closed microtubes at 37°C for 4 hours on a rocking platform. At the end of the incubation, samples were centrifuged for 5 minutes at 500 x g at 4°C, the plasma collected and frozen on dry ice until assayed for the presence of cytokines. TNF levels were determined by ELISA using human recombinant TNF (Genentech Inc., South San Francisco, CA) as a standard.

In later studies it was determined that BPI activity in whole blood is inhibited by heparin, and the anticoagulant was changed to citrate. In these experiments, to 120 µl of citrated whole blood, 20 µl of BPI or an RENP (at 0-1 mg/ml) or buffer control, 20 µl of 100 ng/ml of *E. coli* 055:B5 LPS was added to stimulate cells in whole blood samples. These experiments were performed in polypropylene microtiter plates (Costar, Cambridge, MA). After the 37°C incubation step, the

- 70 -

plates were centrifuged 15 min at 500 x g at 4°C and the plasma removed for assaying.

To test the effects of BPI, LBP, and RENPs on LPS activation of TNF production in whole blood, BPI, LBP,

5 L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D), or B<sub>1-199</sub>L<sub>200-456</sub> was mixed with heparinized blood, and LPS was added to the resulting mixture. The blood was incubated for four hours at 37°C, and TNF in the plasma was measured as described, supra. Results are shown in Figure 10.

10 L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) was the most potent at blocking TNF release, followed by BPI as the next most potent blocker. B<sub>1-199</sub>L<sub>200-456</sub> and LBP had essentially no effect. Thus, in whole blood, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) proved to be the most potent inhibitor of LPS-mediated  
15 cytokine stimulation.

When experiments were performed in citrated rather than heparinized whole blood, endotoxin-neutralizing activity of BPI and L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) were equivalent (Table 6). In experiments in which

20 recombinant proteins were preincubated with endotoxin before addition to whole blood, the activities of these compounds fell roughly into two groups. BPI,

L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D), B<sub>1-199</sub>, B<sub>CAT6</sub>, B<sub>CAT15</sub>,  
L<sub>1-59</sub>B<sub>60-456</sub>, L<sub>1-134</sub>B<sub>135-456</sub>, and L<sub>1-197</sub>B<sub>200-456</sub> possess

25 LPS-neutralizing activity, while LBP, B<sub>1-199</sub>L<sub>200-456</sub>,

L<sub>1-199</sub>, L<sub>1-359</sub>B<sub>360-456</sub> and B<sub>CAT9</sub> were relatively inactive.

Results with L<sub>1-275</sub>B<sub>278-456</sub>, B<sub>CAT9</sub>, and L<sub>(1-198)</sub>B<sub>(201-456)</sub>FC were equivocal. When compounds were added to the blood samples immediately prior to LPS, the IC<sub>50</sub> values were

30 higher, but the same group of proteins showed activity.

These data further indicate the role of the C-terminal region of BPI, demarcated by amino acid residues 200-359, in LPS neutralization in a physiological environment such as whole blood. Because L<sub>1-199</sub> is not a potent

35 endotoxin-neutralizing protein (see Tables 9 and 11), it

- 71 -

can be concluded that the C-terminal domain of BPI must significantly contribute to the endotoxin-neutralizing activity of L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> and L<sub>1-197</sub>B<sub>200-456</sub>. All compounds which contain this sequence (201-359) are  
5 active except B<sub>CAT9</sub>, which was also inactive in other assays possibly because the cationic amino acid residues which were replaced may be important in configuring the molecule. These data indicate that  
L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> is equivalent to L<sub>1-197</sub>B<sub>200-456</sub>  
10 in activity, thus implying that the amino acid differences between these two proteins have no effect upon LPS binding affinity.

- 72 -

Table 6

LPS Inhibition in Human Whole Blood

	Protein Pre- incubated	IC50 ( $\mu\text{g/ml}$ )	n	Not Pre- incubated	IC50 ( $\mu\text{g/ml}$ )	n
5	L <sub>1-134</sub> B <sub>135-456</sub>	0.15 $\pm$ 0.12	3	BPI	2.60 $\pm$ 1.52	5
	L <sub>1-197</sub> B <sub>200-456</sub>	2.90 $\pm$ 3.59	1 2	L <sub>1-134</sub> B <sub>135-456</sub>	3.7 $\pm$ 1.60	2
	L <sub>1-59</sub> B <sub>60-456</sub>	0.28 $\pm$ 0.25	3	L <sub>1-199</sub> (7(143->V)B <sub>200-456</sub> (N206->D))	7.13 $\pm$ 5.92	4
10	L <sub>1-197</sub> (143->V)B <sub>200-456</sub> ( N206->D)	0.16 $\pm$ 0.11	1 7	L <sub>1-59</sub> B <sub>60-456</sub>	15 $\pm$ 18.58	2
	BPI	0.43 $\pm$ 0.49	1 3	L <sub>1-197</sub> B <sub>200-456</sub>	26.5 $\pm$ 0.71	2
	L <sub>(1-198)</sub> B <sub>(201-456)</sub> FC	18.00 $\pm$ 27.73	3	L <sub>1-359</sub> B <sub>360-456</sub>	>100	1
	B <sub>1-199</sub> L <sub>200-456</sub>	>100	3	B <sub>CAT9</sub>	>100	2
	L <sub>1-359</sub> B <sub>360-456</sub>	>100	3	L <sub>(1-198)</sub> B <sub>(201-456)</sub> FC	>100	2
15	B <sub>CAT9</sub>	11.50 $\pm$ 3.54	2 *	B <sub>1-199</sub> L <sub>200-456</sub>	ND	
	B <sub>1-199</sub>	0.73 $\pm$ 0.48	6	B <sub>1-199</sub>	4.0	1
	L <sub>1-199</sub>	>100	2	L <sub>1-199</sub>	>100	1
	B <sub>CAT15</sub>	0.21 $\pm$ 0.26	3			
	B <sub>CAT8</sub>	0.27 $\pm$ 0.25	2			
20	L <sub>(1-134)</sub> B <sub>(136-275)</sub> L <sub>(274-456)</sub>	2.0	1			
	L <sub>(1-198)</sub> B <sub>(202-275)</sub> L <sub>(274-456)</sub>	5.27 $\pm$ 5.83	3			
	L <sub>1-275</sub> B <sub>276-456</sub>	38.10 $\pm$ 53.64	3			

25 \*Two additional values for B<sub>CAT9</sub> were >100.

- 73 -

Example 11: Mouse Serum Half-Life Assay

CD-1 mice weighing approximately 20 grams were injected with 5 mg/kg body weight BPI, LBP, or RENPs (1 mg/ml) at time zero. In heparinized (or later  
5 EDTA-containing) tubes, blood was collected from the retroorbital plexus from three animals for each time point tested. A typical blood collection schedule was 5, 10, 15, 30, 45, 60, 90, 120, 240, and 360 minutes. The EDTA anticoagulated blood was centrifuged for about  
10 10 min at 1000 x g and the supernatant plasma removed and stored frozen on dry ice until tested. Levels of BPI, LBP, or RENP in the plasma samples were determined by ELISA using the appropriate protein as the standard.

A potent anti-endotoxin therapeutic should not  
15 only neutralize endotoxin, but should also have the capacity to clear endotoxin from the circulation. The circulating levels of radioactively labeled  $^{125}\text{I}$ -BPI were measured in the mouse in the presence and absence of endotoxin (Table 7). In the absence of endotoxin, the  
20 elimination (alpha) phase for  $^{125}\text{I}$ -BPI was less than two minutes. In the presence of LPS, the alpha phase was extended to 6.2 minutes.  $^{125}\text{I}$ -LPS alone has a single phase distribution (beta) with a half-life of about 101 minutes. When  $^{125}\text{I}$ -LPS and unlabeled BPI were  
25 administered, a 6.2 minute elimination (alpha) phase was observed, indicating that elimination was remarkably facilitated by BPI.

- 74 -

Table 7Serum Half-Life of BPI and LPS in the Mouse

<u>Test Article</u>	<u>t<sub>1/2</sub>alpha</u>	<u>t<sub>1/2</sub>beta</u>
<sup>125</sup> I-BPI	1.6	103.0
<sup>125</sup> I-BPI + LPS	6.3	72.0
<sup>125</sup> I-LPS	---	101.0
<sup>125</sup> I-LPS + BPI	6.2	114.0

10

In order to determine whether the very short circulating half-life of BPI could be extended by molecular engineering, the circulating half-lives of BPI, LBP, B<sub>1-199</sub>L<sub>200-456</sub> and L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> were compared (Figure 11). Using both labeled and unlabeled material, it was observed that the circulating half-life of BPI in the mouse is remarkably short. This may be a result of the highly cationic nature of BPI having a predicted pI of 10.6. LBP, normally present in the circulation at concentrations of 10 µg/ml, has a predicted pI of about 6.8. As expected, L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> (LBP-BPI chimera lacking BPI cationic residues) has a markedly longer circulating half-life than B<sub>1-199</sub>L<sub>200-456</sub> (BPI-LBP chimera having BPI cationic residues). Figure 11 shows that L<sub>1-197(I43->V)</sub>B<sub>200-456(N206->D)</sub> indeed has a longer half-life than BPI. B<sub>1-199</sub>L<sub>200-456</sub>, with the N-terminal domain of BPI, had an even shorter half-life than that of BPI. Thus, the N-terminal domain of BPI appears to play a major role in its short circulating half-life.

Further pharmacokinetic studies were performed in which recombinant proteins of the subject invention were administered to CD-1 mice at a 5 mg/kg bolus dose. Results of these experiments are shown in Figures



- 75 -

- 17A-17H. At 5 mg/kg, the circulating half life of  $B_{1-199}L_{200-456}$  was similar to that of BPI.
- $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  and  $L_{1-197}B_{200-456}$  had overlapping elimination curves and again indicating that
- 5 these two molecules are equivalent with respect to their biological activities.  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  and  $B_{1-199}$  persisted in the circulation significantly longer than BPI or  $B_{1-199}L_{200-456}$ , but not as long as the serum protein LBP. Comparison of the elimination curves of
- 10  $L_{1-59}B_{60-456}$ ,  $L_{1-134}B_{135-456}$  and  $B_{CAT9}$  revealed that the N-terminus of LBP plays a role in extending circulating half-life.  $L_{1-59}B_{60-456}$  circulates slightly longer than BPI, and contains the least LBP sequence of any of the recombinant proteins tested (amino acid residues 1-59).
- 15  $L_{1-134}B_{135-456}$  was cleared somewhat more slowly, indicating that LBP amino acid residues 60-134 of LBP impart a longer circulating half-life. In contrast, the cationic residues of BPI between 134-199 shorten the half-life, since in  $B_{CAT9}$ , where the cationic residues in this region
- 20 were replaced with the corresponding residues of LBP, the half-life was similar to that of  $L_{1-134}B_{135-456}$ . Including more LBP residues in the N-terminal domain further extends the half life. If amino acid residues 199-359 of LBP are added ( $L_{1-359}B_{360-456}$ ), the half-life is longer,
- 25 but not quite as long as that of LBP. Likewise  $L_{(1-198)}B_{(202-275)}L_{(274-456)}$  (with LBP domain 1-198 and 274-456) has a relatively long  $t_{1/2}$ . These results indicate that the more "LBP-like" the molecule is, the longer it circulates. In addition, combining an Ig
- 30 fragment Fc with  $L_{1-197}(I43 \rightarrow V)B_{200-456}(N206 \rightarrow D)$  gives the longest half life.

#### Example 13: Mouse Endotoxin Challenge Assay

Femal CD-1 mic w re inj cted in the lateral tail v in with a  $LD_{100}$  dos (25-35 mg/kg) of Salmonella abortus

- 76 -

- equi endotoxin, which was followed by an injection of BPI, RENP, or vehicle control into the opposite lateral tail vein at the indicated time. Protein injection concentrations varied and provided doses of 0.5, 1, and 5 mg/kg. Use of vehicle control illustrated the lethality of the endotoxin challenge in the test animal. Animals were observed for mortality at 24, 28, and 72 hours. Preliminary studies showed that mortality does not change from day three to day seven or beyond.
- 10        The efficacies of BPI, LBP, L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D), B<sub>1-199</sub>L<sub>200-456</sub> and B<sub>(S351->A)</sub> against lethal endotoxin challenge in mice were compared (Tables 8-10). The efficacies of L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D), L<sub>1-197</sub>B<sub>200-456</sub>, L<sub>1-59</sub>B<sub>60-456</sub>, 15 L<sub>1-134</sub>B<sub>135-456</sub>, L<sub>(1-198)</sub>B<sub>(201-456)</sub>FC, L<sub>1-275</sub>B<sub>278-456</sub>, L<sub>1-359</sub>B<sub>360-456</sub>, B<sub>CAT9</sub>, B<sub>CAT6</sub>, and B<sub>CAT15</sub> against lethal endotoxin challenge in mice were also compared (Table 11). When each protein was given within two minutes after lethal endotoxin challenge, BPI, 20 L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) and B<sub>(S351->A)</sub> had similar potency, whereas LBP and B<sub>1-199</sub>L<sub>200-456</sub> showed minimal protection. The marginal protective effects of LBP and B<sub>1-199</sub>L<sub>200-456</sub> since these agents do not block the inflammatory signal of LPS acting on human cells *in vitro* 25 (Figure 10).

- 77 -

Table 8

5 Mouse Endotoxin Challenge  
Comparison of BPI, LBP (NCY102),  
and L<sub>1</sub>-197 (I43->V) B<sub>200-456</sub> (N206->D) (NCY103)

<u>Drug</u>	<u>Dose</u>	<u>% Survival (n=10)</u>	
Control	0 mg/kg	0%	
10 BPI	5 mg/kg	60%	
	1 mg/kg	40%	
LBP	5 mg/kg	30%	
	1 mg/kg	20%	
L <sub>1</sub> -197 (I43->V) B <sub>200-456</sub> (N206->D)	5 mg/kg	5 mg/kg	60%
	1 mg/kg	50%	

15

Table 9

20 Mouse Endotoxin Challenge  
Comparison of BPI, L<sub>1</sub>-197 (I43->V) B<sub>200-456</sub> (N206->D) and  
B<sub>(S351->A)</sub>

<u>Drug</u>	<u>Dose</u>	<u>% Survival (n=10)</u>	
Control	0 mg/kg	0%	
BPI	5 mg/kg	80%	
25 L <sub>1</sub> -197 (I43->V) B <sub>200-456</sub> (N206->D)	5 mg/kg	5 mg/kg	100%
	B <sub>(S351-&gt;A)</sub>	5 mg/kg	90%

- 78 -

Table 10

5 Mouse Endotoxin Challenge  
Comparison of BPI and B<sub>1-199</sub>L<sub>200-456</sub> (NCY104)

<u>Drug</u>	<u>Dose</u>	<u>% Survival (n=10)</u>
Control	0 mg/kg	40%
10 BPI	10 mg/kg	100%
	2 mg/kg	100%
	0.4 mg/kg	70%
B <sub>1-199</sub> L <sub>200-456</sub>	10 mg/kg	60%
	2 mg/kg	60%
	0.2 mg/kg	50%

15

Table 11

20 Survival in CD-1 Mice Following  
Lethal Endotoxin Challenge

Panel A

	<u>Survivors/n</u>	<u>% Survival</u>	<u>P</u> <u>(vs.control)</u>
BPI	40/50	80.00	< 0.001
25 L <sub>1-197</sub> (I43->V)B <sub>200-456</sub> (N206->D)	17/20	85.00	< 0.001
0.001			
L <sub>1-197</sub> B <sub>200-456</sub>	16/20	80.00	< 0.001
L <sub>1-59</sub> B <sub>60-456</sub>	13/20	65.00	< 0.001
L <sub>1-134</sub> B <sub>135-456</sub>	13/20	65.00	< 0.001
30 L <sub>(1-198)</sub> B <sub>(201-456)</sub> FC	5/10	50.00	0.002
L <sub>1-359</sub> B <sub>360-456</sub>	2/10	20.00	0.149
B <sub>CAT6</sub>	9/10	90.00	< 0.001
B <sub>CAT9</sub>	1/10	10.00	0.442
L <sub>1-275</sub> B <sub>278-456</sub>	0/10	0	--
35 B <sub>CAT15</sub>	6/10	60.0	< 0.05
Control	1/30	3.30	--

- 79 -

Panel B

	<u>Dose</u> <u>mg/kg</u>	<u>Survivors</u> <u>(n=20)</u>	<u>%</u> <u>Survival</u>	<u>p</u> <u>(vs. control)*</u>
<b>BPI</b>				
5	5	13	65	< 0.001
	1	9	45	0.001
	0.5	6	30	0.02
<b>L<sub>1-197</sub>(I43-&gt;V)B<sub>200-456</sub>(N206-&gt;D)</b>				
10	5	18	90	<0.001
	1	12	60	<0.001
	0.5	9	45	0.001
<b>B<sub>1-199</sub></b>				
15	5	3	15	NS
	1	0	0	NS
	0.5	1	5	NS

\* Fisher's Exact Test

20 L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) was markedly more effective than BPI when given more than an hour before or after LPS (Figure 12). These results indicate that the longer circulating half-life of

25 L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D), or perhaps the increased ability of L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) to inhibit endotoxin in whole blood, has a dramatic effect on

L<sub>1-197</sub>(I43->V)B<sub>200-456</sub>(N206->D) efficacy *in vivo*.

Further experiments were performed to assess the LPS-neutralizing activities of recombinant proteins of

30 the subject invention *in vivo*. In these experiments, a lethal LPS challenge was administered at time zero, followed immediately by a 5 mg/kg bolus injection of recombinant protein.

- 80 -

Example 12: BPI Reduction of LPS-Induced Cytokine  
Function and Mortality in Rats

The potential effect of BPI against LPS related cytokine formation and mortality was investigated in rats with either (a) hemorrhagic shock (bled to lower pressure to 30-35 mmHg mean arterial pressure for 90 minutes, followed by reinfusion of shed blood and an equal volume of Ringer's over 30 minutes), or (b) endotoxic shock (caused by 100  $\mu$ g LPS and 500 mg D-galactosamine/ kg). Similarly, recombinant BPI binds LPS and inhibits TNF formation *in vitro*. Treatment comprised 5 mg BPI/kg i.v. for the BPI group, or 1 ml saline i.v. for the control group.

The results of the investigation of BPI efficacy in rats with either (a) hemorrhagic shock or (b) endotoxic shock show that (a) in rats with hemorrhagic shock, the mortality was decreased from 5/10 (50% control group) to 2/10 (20% BPI group) at 48 hours; (b) in rats with endotoxic shock, the 5-day mortality was significantly reduced ( $p = 0.055$ ) by BPI treatment to 43%, as compared to 83% in the control group. Plasma LPS levels were at least partially neutralized at two hours ( $5.9 \pm 4.1$  vs  $10.8 \pm 4.1$  ng/ml). Cytokine formation was concomitantly reduced in the BPI group as measured by plasma TNF levels at two hours ( $3.9 \pm 2.9$  vs  $10.3 \pm 6.3$  ng/ml). Liver transaminases (GOT and GPT, whose elevation indicates hepatic dysfunction) and bilirubin still increased at eight hours; however, the increase was less with BPI. These data demonstrate that BPI has utility as a therapeutic agent against endotoxin-related disorders in hemorrhagic as well as endotoxic shock.

- 81 -

Example 14: Protection against LPS challenge by intrapulmonary delivery of RENPs

Anesthetized male CD-1 mice were treated intra-nasally with 1 or 10  $\mu$ g of either BPI or

5 L<sub>1</sub>-197(I43->V)<sup>B</sup><sub>200-456</sub>(N206->D) in 50  $\mu$ l. Control animals received 50  $\mu$ l of saline for injection. After 20 minutes, animals were re-anesthetized, and challenged with 10 ng of *E. coli* 055:B5 LPS. One hour after endotoxin challenge, mice were re-anesthetized, and

10 0.7 ml of saline containing 1% human serum albumin was added to the lungs via the trachea. The lungs were gently kneaded. A 0.5 ml volume of BAL (bronchoalveolar lavage) fluid was aspirated, cells were pelleted by centrifugation, and the BAL sample was sorted at -70°C.

15 The TNF-alpha level in the BAL fluid was determined by ELISA (results shown in Figure 19).

Figure 19 shows that endotoxin-neutralizing proteins such as BPI and L<sub>1</sub>-197(I43->V)<sup>B</sup><sub>200-456</sub>(N206->D) (NCY103) can also neutralize endotoxin-mediated TNF

20 release in the lung. These results indicate that these proteins are effective when delivered directly into the lung and thus may be useful for treatment of pneumonias and other endotoxin-related disorders of the lung, such as ARDS.

25 Example 15. Construction of L<sub>1</sub>-197<sup>B</sup><sub>200-456</sub>

cdNA encoding L<sub>1</sub>-197<sup>B</sup><sub>200-456</sub> was constructed by creating a unique ClaI site at the junction between the nucleotide sequence coding for Ile<sub>197</sub>-Asp<sub>198</sub> residues (ATA-GAT -> ATC-GAT). For L<sub>1</sub>-197<sup>B</sup><sub>200-456</sub>, a 0.7 kb

30 NheI/ClaI DNA fragment (encoding amino acids 1-197) derived from the 5' sequence of LBP and a 0.8 kb ClaI/XhoI fragment (encoding amino acids 200-456) derived from the 3' sequence of BPI were generated by PCR. The chimeric cDNAs were spliced together by cloning the

- 82 -

fragments into pSE, a mammalian vector. The cDNAs for BPI, LBP and L<sub>1-197</sub>B<sub>200-456</sub> were transfected into Chinese hamster ovary cells (strain DUXB11) using lipofectin. The resulting transformed cells were selected, and  
5 expression was amplified with methotrexate. Cell culture supernatants were screened for reactivity by ELISA. Recombinant BPI, LBP, and L<sub>1-197</sub>B<sub>200-456</sub> were purified as described above.

Example 16. Pharmokinetics of L<sub>1-197</sub>B<sub>200-456</sub>

- 10 Data for pharmacokinetic analysis were collected from healthy CD-1 mice given a single bolus injection (5 mg/kg) of recombinant protein at time=0. Blood was collected from three mice for each collection time point by retroorbital puncture at timepoints over three hours.  
15 Blood samples anticoagulated in EDTA were assayed by a double antibody sandwich ELISA for the presence of BPI, LBP or L<sub>1-197</sub>B<sub>200-456</sub>). Pharmacokinetic analysis was performed using a non-compartmental analysis (PharmK pharmacokinetic software, SoftRes, Inc.).  
20 Comparison of BPI and LBP shows that BPI was cleared rapidly with a clearance rate of 13.0 ml/minute (Table 12). LBP had the longest half life, with a clearance rate of 0.042 ml/min. Compared to BPI, LBP was cleared 310 times more slowly. L<sub>1-197</sub>B<sub>200-456</sub> had an  
25 intermediate half life (Clearance rate = 0.175 ml/min), being cleared 74 times more slowly than BPI.

Table 12: Clearance rate of L<sub>1-197</sub>B<sub>200-456</sub>

	CL (ml/min)	(vs. BPI)
BPI	13.000	-
LBP	0.042	(310 fold)
30 L <sub>1-197</sub> B <sub>200-456</sub>	0.175	(74 fold)



- 83 -

Exempl 17. LPS protection by L<sub>1-197</sub>B<sub>200-456</sub>

Female CD-1 mice (n=10) were injected in the lateral tail vein with 35 mg/kg S. abortus equi LPS (Sigma, St. Louis, MO) at time=0. Recombinant protein (5 mg/kg) was then administered intravenously into the opposite lateral tail vein immediately following (t=0) endotoxin challenge. Survival was monitored at 24, 48 and 72 hours post-challenge. Control animals received 0.1 ml saline instead of recombinant protein. The p values were determined by Fisher's exact test.

The results are shown in Figure 20. BPI and L<sub>1-197</sub>B<sub>200-456</sub> provided 90% to 100% survival, respectively, at the 72 hour end point. No further mortality was noted at seven days post-challenge. The untreated control group had a survival rate of 20%. The survival rates of the treated groups were statistically significant compared to the control group (p<.001 for the L<sub>1-197</sub>B<sub>200-456</sub> group and p=.003 for the BPI group determined by Fisher's exact test). These results indicate that L<sub>1-197</sub>B<sub>200-456</sub> is as effective as BPI in this endotoxin challenge model in vivo.

Example 18. Protection Against Endotoxin Challenge in Mice

The ability of the recombinant, endotoxin-neutralizing proteins B<sub>(1-41)</sub>L<sub>(1-199)</sub>B<sub>(1-456)</sub>, L<sub>(1-164)</sub>B<sub>(200-456)</sub>, B<sub>(1-175)</sub>B<sub>(200-456)</sub>, B<sub>(1-236)</sub>, and B<sub>(1-190)</sub> to protect mice against endotoxin challenge was carried out as described in Example 17 above. Protection by these proteins was compared to the protection provided by BPI or saline. The results of these studies are shown in Tabl 13.

- 84 -

**TABLE 13**

	Compound	Lot #	Number of Survivors/10 at Time (hours)							
			0	12	18	24	36	48	60	72
5	Group 1	native BPI	149724	10	10	10	10	10	9	9
	Group 2	B <sub>(1-41)</sub> L <sub>(1-199)</sub> B <sub>(1-456)</sub>	162303	10	10	10	10	9	9	8
	Group 3	L <sub>(1-164)</sub> B <sub>(200-456)</sub>	164325	10	10	9	9	8	8	7
	Group 4	L <sub>(1-175)</sub> B <sub>(200-456)</sub>	164326	10	10	10	10	10	10	10
10	Group 5	B <sub>(1-236)</sub>	159695	8	7	5	4	1	0	0
	Group 6	B <sub>(1-190)</sub>	159699	10	9	8	6	6	6	5
15	Group 7	Saline		10	8	7	6	4	3	3

Each animal received 35 mg/kg LPS in 0.1 ml, followed immediately by 5 mg/kg of the indicated compound in 0.1 ml. Survival was monitored at each time point indicated.

**20 Example 19: Detection of a Gram-negative infection in a patient**

A blood sample of about 1 ml to 5 ml is drawn from a patient suspected of having a Gram-negative infection. The blood sample is treated with citrate anti-coagulant and plasma is separated from the blood cells by centrifugation. The plasma is then diluted in a series of 10-fold dilutions in assay buffer (pyrogen-free TBS + 1 mg/ml low endotoxin BSA, and 0.05% Tween-20). The diluted plasma samples are then mixed with a known amount of biotinylated RENP. A series of control samples containing known amounts of biotinylated RENP in assay

- 85 -

buffer is included in the assay as quantitative and negative controls.

- The test and control samples are then applied to the wells of a microtiter plate having bound LPS. The
- 5 LPS-bound microtiter wells are prepared by incubation with 1 or 4  $\mu$ g of S. minnesota R595 Re LPS (LIST Biological Labs, Inc., #304) in 50 mM borate pH 9.5-9.8 + 20-25 mM EDTA overnight at 37°C. Blank, non-LPS coated wells are included on each plate as controls for
- 10 non-specific binding. The plates are then washed extensively under running distilled deionized water, then dried at 37°C. The assay wells are subsequently blocked for 60 minutes at 37°C with 1-2% very low endotoxin BSA (Sigma, St. Louis, MO) prepared in pyrogen-free
- 15 Tris-buffered saline (50 mM Tris pH 7.4 + 150 mM NaCl).

- The test and control samples are incubated for a time sufficient for binding of the RENP in the samples to the LPS bound to the microtiter wells, generally about 2-3 hours at 37°C in a total volume of 100  $\mu$ l/well.
- 20 After incubation, the wells are washed four times with assay buffer, and the plates are developed with streptavidin conjugated to alkaline phosphatase followed by 100  $\mu$ l of PNP substrate solution freshly prepared from two 5 mg tablets dissolved in 10 ml substrate buffer.
- 25 Substrate buffer is prepared with 24.5 mg  $MgCl_2$ , 48 ml diethanolamine, brought up to 400 ml, pH adjusted to 9.8 and volume brought up to 500 ml. Absorbances are read at 405 nm on a microplate reader.

- If the level of biotinylated RENP bound to the
- 30 wells of the test sample is significantly less than the level of biotinylated RENP bound to the negative control sample, then the patient has endotoxin circulating in the bloodstream which is generally associated with a Gram-negative infection. Moreover, the level of RENP
- 35 binding in the test sample is compared to the levels of

- 86 -

RENp binding in the quantitative controls, each of which are representative of varying degrees of severity of Gram-negative infection in a patient. The level of binding of the test sample is thus compared to the levels of binding of the quantitative samples to determine a degree of severity of infection.

Example 20: Detection of a Gram-negative infection in vivo

RENp is detectably labeled with  $^{125}\text{I}$  using methods well known in the art. Approximately 100  $\mu\text{g}$  of an  $^{125}\text{I}$ -labeled RENp is injected intravenously into a patient suspected of having a Gram-negative infection in an organ, e.g., the liver. After allowing a time sufficient for circulation of the  $^{125}\text{I}$ -labeled RENp to the suspected site of infection, the abdomen of the patient is fluoroscoped or X-rayed 2 to 3 times so as to include various perspectives. The X-ray is then examined to identify sites of binding of the RENp by virtue of an abnormally darkened section on the X-ray. Upon identification of the site of infection, the clinician designs an appropriate therapeutic regimen.

Following procedures similar to those described above, other recombinant, LPS-binding proteins can be produced and used in diagnostic methods and methods of treatment according to the invention.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

## CLAIMS

- 87 -

1. A method of detecting a site of Gram-negative bacterial infection in a subject, said method comprising the steps of:

injecting into the patient's circulatory system an  
5 injectable formulation comprising an effective amount of a recombinant endotoxin-neutralizing polypeptide attached to a detectable label, wherein the polypeptide is characterized by (i) selective and specific binding to lipopolysaccharide and (ii) endotoxin-neutralizing  
10 activity, with the proviso that the amino acid sequence of the polypeptide is not identical to the amino acid sequences of BPI or LBP;

allowing the detectably labeled polypeptide sufficient time to circulate in the subject and bind to  
15 lipopolysaccharide in the patient; and

detecting a site of label binding in the patient, thereby detecting a site of Gram-negative bacterial infection.

2. The method of claim 1, wherein the  
20 polypeptide is covalently bound to a molecule which enhances the half-life of the polypeptide.

3. The method of claim 1, wherein the polypeptide contains an LPS binding domain of BPI, LBP, a BPI variant, or an LBP variant.

25 4. The method of claim 1, wherein the detectable label is a radionucleotide.

- 88 -

5. A method for detecting a Gram-negative bacterial infection in a subject, said method comprising the steps of:

- obtaining a sample from a patient suspected of  
5 having a Gram-negative bacterial infection;  
contacting said sample with a detectably labeled recombinant endotoxin-neutralizing polypeptide for a time sufficient for binding of the polypeptide to lipopolysaccharide in the sample; and  
10 detecting formation of lipopolysaccharide-polypeptide complexes by detection of a detectable label bound to the polypeptide;  
wherein detection of a level of detectable label in said sample significantly greater than a level of  
15 detectable label in a negative control sample is indicative of a Gram-negative bacterial infection in the subject.

6. The method of claim 5, wherein the polypeptide contains an LPS binding domain of BPI, LBP, a  
20 BPI variant, or an LBP variant.

7. The method of claim 5, wherein said detection is quantitative.

8. The method of claim 7, wherein said quantitative detection is correlated with an  
25 Gram-negative bacterial infection load.

- 89 -

9. A detectably labeled recombinant endotoxin-neutralizing polypeptide characterized by (i) selective and specific binding to lipopolysaccharide and (ii) endotoxin-neutralizing activity, with the proviso that the amino acid sequence of the polypeptide is not identical to the amino acid sequences of BPI or LBP.

10. A polypeptide according to claim 9, wherein the polypeptide contains an LPS binding domain of BPI, LBP, a BPI variant, or an LBP variant.

11. A detectably labeled polypeptide according to claim 9, wherein the polypeptide comprises a molecule which enhances the half-life of said polypeptide and is covalently bound to the polypeptide.

12. A detectably labeled polypeptide according to claim 11, wherein said molecule is an immunoglobulin fragment, a half-life enhancing portion of LBP, a half-life enhancing portion of an LBP variant, or polyethylene glycol.

13. A kit for detecting a site of Gram-negative bacterial infection in a subject, the kit comprising:  
an injectable formulation comprising a detectably labeled recombinant endotoxin-neutralizing polypeptide characterized by (i) selective and specific binding to lipopolysaccharide and (ii) endotoxin-neutralizing activity, with the proviso that the amino acid sequence of the polypeptide is not identical to the amino acid sequences of BPI or LBP.

- 90 -

14. A recombinant endotoxin-neutralizing polypeptide characterized by (i) selective and specific binding to lipopolysaccharide and (ii) endotoxin-neutralizing activity, with the proviso  
5 that the amino acid sequence of the polypeptide is not identical to the amino acid sequences of BPI or LBP.

15. A recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein said polypeptide is of the formula  $L_{1-197}B_{200-456}$  or a  
10 corresponding protein which (a) functions to bind lipopolysaccharide and (b) neutralizes endotoxin.

16. A recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein the polypeptide is BPI(S351->X), wherein X is any amino acid  
15 other than serine.

17. A recombinant endotoxin-neutralizing polypeptide according to claim 16, wherein X is alanine.

18. A recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein the  
20 polypeptide contains the amino acid sequence of BPI having a cationic amino acid substituted with a neutral or anionic residue.

19. A recombinant endotoxin-neutralizing polypeptide according to claim 18, wherein the cationic  
25 amino acid is at BPI amino acid residue positions 27, 30, 33, 42, 44, 48, 59, 77, 86, 90, 96, 118, 127, 148, 150, 160, 161, 167, 169, 177, 185, or 198.



- 91 -

20. A recombinant endotoxin-neutralizing polypeptide according to claim 19, wherein the polypeptide contains neutral or anionic residues at BPI amino acid residue positions 27, 30, 33, 42, 44, 48, and  
5 59.

21. A recombinant endotoxin-neutralizing polypeptide according to claim 19, wherein the polypeptide contains neutral or anionic residues at BPI amino acid residue positions 77, 86, 90, 96, 118, and  
10 127.

22. A recombinant endotoxin-neutralizing polypeptide according to claim 19, wherein the polypeptide contains neutral or anionic residues at BPI amino acid residue positions 148, 150, 160, 161, 167,  
15 169, 177, 185, and 198.

23. A recombinant endotoxin-neutralizing polypeptide according to claim 18, wherein the polypeptide contains neutral or anionic residues at BPI amino acid residue positions 27, 30, 33, 42, 44, 48, 59,  
20 77, 86, 90, 96, 118, 127, 148, 150, 160, 161, 167, 169, 177, 185, and 198.

24. A recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein the polypeptide contains the amino acid sequence of LBP  
25 having an amino acid substituted for an amino acid in a corresponding amino acid residue position of BPI.

- 92 -

25. A recombinant endotoxin-neutralizing polypeptide according to claim 24, wherein the amino acid substituted is at LBP amino acid residue positions 77, 86, 96, 118, 126, 147, 148, 158, 159, 161, 165, 167, 175, 5 183, or 196.

26. A recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein the polypeptide contains the amino acid sequence of BPI having a cysteine residue substituted with an amino acid 10 other than cysteine.

27. A recombinant endotoxin-neutralizing polypeptide according to claim 26, wherein said cysteine residue is at BPI amino acid residue position 132, 135, or 175.

15 28. A recombinant endotoxin-neutralizing polypeptide according to claim 26, wherein the cysteine residues of BPI at positions 132, 135, and 175 are substituted with an amino acid other than cysteine.

29. A recombinant endotoxin-neutralizing 20 polypeptide according to claim 14, wherein the polypeptide comprises a molecule which enhances the half-life of said polypeptide and is covalently bound to the polypeptide.

30. A recombinant endotoxin-neutralizing 25 polypeptide according to claim 29, wherein said polypeptide contains a lipopolysaccharide-binding domain of BPI, LBP, a BPI variant, or an LBP variant.

- 93 -

31. A recombinant endotoxin-neutralizing polypeptide according to claim 29, wherein said molecule is an immunoglobulin fragment, a half-life enhancing portion of LBP, a half-life enhancing portion of an LBP variant, or polyethylene glycol.

32. A recombinant endotoxin-neutralizing polypeptide according to claim 29, wherein the endotoxin-neutralizing polypeptide of (a) is a C-terminal fragment of BPI and the molecule of (b) is an N-terminal  
10 fragment of LBP.

33. A recombinant endotoxin-neutralizing polypeptide according to claim 32, wherein said C-terminal fragment of BPI is a fragment having an amino acid sequence contained in BPI amino acid residues  
15 60-456.

34. A recombinant endotoxin-neutralizing polypeptide according to claim 33, wherein said C-terminal fragment of BPI is BPI amino acid residues 60-456, 136-456, 277-456, 300-456, 200-456, 136-361,  
20 136-275, 200-275, or 200-361.

35. A recombinant endotoxin-neutralizing polypeptide according to claim 32, wherein said N-terminal fragment of LBP is a fragment having an amino acid sequence contained in LBP amino acid residues 1-175.

25 36. A recombinant endotoxin-neutralizing polypeptide according to claim 21, wherein said N-terminal fragment of LBP is LBP amino acid residues 1-59, 1-134, 1-164, 1-175, 1-274, 1-359, 1-134, or 1-197.

- 94 -

37. A recombinant endotoxin-neutralizing polypeptide of claim 18, wherein the polypeptide further comprises a C-terminal fragment of LBP.

38. A recombinant endotoxin-neutralizing polypeptide of claim 23, wherein the C-terminal fragment of LBP is LBP amino acid residues 360-456 or 274-456.

39. An isolated DNA molecule encoding a recombinant endotoxin binding polypeptide according to claim 14.

40. A vector comprising the DNA of claim 39.

41. A transformed host cell comprising the DNA of claim 39.

42. A method for producing a recombinant endotoxin-neutralizing polypeptide according to claim 14, said method comprising the steps of:

culturing a transformed host cell comprising DNA encoding a recombinant endotoxin binding polypeptide according to claim 14, said DNA being operably linked to a promoter for expression of the polypeptide encoded by the DNA, said culturing being under conditions allowing expression of said polypeptide; and isolating the recombinant endotoxin binding polypeptide produced.

43. A pharmaceutical composition comprising:  
a therapeutically effective amount of a recombinant endotoxin-neutralizing polypeptide according to claim 14; and  
a pharmaceutically acceptable carrier.

- 95 -

44. A method of treating a subject suffering from an endotoxin-related disorder, said method comprising:

administering to a subject having an endotoxin-related disorder a therapeutically effective  
5 amount of a recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein LPS-mediated stimulation of neutrophils and mononuclear cells is inhibited.

45. A method of preventing an endotoxin-related  
10 disorder in a subject, said method comprising:

administering to a subject a prophylactically effective amount of a recombinant endotoxin-neutralizing polypeptide according to claim 14, wherein the endotoxin-related disorder is prevented.

## FIGURE 1A

FIGURE 1A
FIGURE 1B
FIGURE 1C
FIGURE 1D

-25-

1.311-1 (as reported by Schumann et al.)

1.1311-b (correct sequence)

-20-

10

1/39

01

20

30

40

50

60

70

11:00 AM  
11:00 AM

11-11-11  
11-11-11

**FIGURE 1B**

	80	90	100
Human	I S L S I S D S S I R V Q G R W K V R K S F F K I		
Human	I S L S I S D S S I R V Q G R W K V R K S F F K I		
Human	Q G S F D V S V K G I S I S V N L L L G S E S S	110	120
Human	Q G S F D V S V K G I S I S V N L L L G S E S S		
Human	G R P T G C Y L S C S S D I A D V E V D M S G D	130	140
Human	G R P T V T A S S C S S D I A D V E V D M S G D		
Human	† † † †		
Human	S G W L L N L F H N Q I E S K F Q K V L E S R I C	150	160
Human	F G W L L N L F H N Q I E S K F Q K V L E S R I C		
Human	E M I Q K S V S S S D L Q P Y L Q T L P V T T E I D	180	190
Human	E M I Q K S V S S S D L Q P Y L Q T L P V T T E I D		








5/39

Figure 2



6/39

FIGURE 3A  
FIGURE 3B  
FIGURE 3C  
FIGURE 3D

FIGURE 3A

I CDNA																	
1	CAG	GCC	TTG	AGG	TTT	TGG	CAG	CTC	TGG	AGG	ATG	AGA	GAG	AAC	ATG	GCC	48
1											Met	Arg	Glu	Asn	Met	Ala	6
49	AGG	GGC	CCT	TGC	AAC	GCG	CCG	AGA	TGG	GTG	TCC	CTG	ATG	GTG	CTC	GTC	96
7	Arg	Gly	Pro	Cys	Asn	Ala	Pro	Arg	Tyr	Val	Ser	Leu	Met	Val	Leu	Val	22
97	GCC	ATA	GGC	ACC	GCC	GTG	ACA	GCG	GCC	GTC	AAC	CCT	GGC	GTC	GTG	GTC	144
23	Ala	Ile	Gly	Thr	Ala	Val	Thr	Ala	Ala	Val	Asn	Pro	Gly	Val	Val	Val	38
145	AGG	ATC	TCC	CAG	AAG	GGC	CTG	GAC	TAC	GCC	AGC	CAG	CAG	GGG	ACG	GCC	192
39	Arg	Ile	Ser	Gln	Lys	Gly	Leu	Asp	Tyr	Ala	Ser	Gln	Gln	Gly	Thr	Ala	54
193	GCT	CTG	CAG	AAG	GAG	CTG	AAG	AGG	ATC	AAG	ATT	CCT	GAC	TAC	TCA	GAC	240
55	Ala	Leu	Gln	Lys	Glu	Leu	Lys	Arg	Ile	Lys	Ile	Pro	Asp	Tyr	Ser	Asp	70
241	AGC	TTT	AAG	ATC	AAG	CAT	CTT	GGG	AAG	GGG	CAT	TAT	AGC	TTC	TAC	AGC	288
71	Ser	Phe	Lys	Ile	Lys	His	Leu	Gly	Lys	Gly	His	Tyr	Ser	Phe	Tyr	Ser	86
289	ATG	GAC	ATC	CGT	GAA	TTC	CAG	CTT	CCC	AGT	TCC	CAG	ATA	AGC	ATG	GTG	336
87	Met	Asp	Ile	Arg	Glu	Phe	Gln	Leu	Pro	Ser	Ser	Gln	Ile	Ser	Met	Val	102

7/39

FIGURE 3B

337	CCC	AAT	GTG	GGC	CTT	AAG	TTC	TCC	ATC	AGC	AAC	GCC	AAT	ATC	AAG	ATC	384
103	Pro	Asn	Val	Gly	Leu	Lys	Phe	Ser	Ile	Ser	Asn	Ala	Asn	Ile	Lys	Ile	118
385	AGC	GGG	AAA	TGG	AAG	GCA	CAA	AAG	AGA	TTC	TTA	AAA	ATG	AGC	GGC	AAT	412
119	Ser	Gly	Lys	Trp	Lys	Ala	Gln	Lys	Arg	Phe	Leu	Lys	Met	Ser	Gly	Asn	134
433	TTT	GAC	CTG	AGC	ATA	GAA	GGC	ATG	TCC	ATT	TCG	GCT	GAT	CTG	AAG	CTG	480
135	Phe	Asp	Leu	Ser	Ile	Glu	Gly	Met	Ser	Ile	Ser	Ala	Asp	Leu	Lys	Leu	150
481	GGC	AGT	AAC	CCC	ACG	TCA	GGC	AAG	CCC	ACC	ATC	ACC	TGC	TCC	AGC	TGC	528
151	Gly	Ser	Asn	Pro	Thr	Ser	Gly	Lys	Pro	Thr	Ile	Thr	Cys	Ser	Ser	Cys	166
529	AGC	AGC	CAC	ATC	AAC	AGT	GTC	CAC	GTG	CAC	ATC	TCA	AAG	AGC	AAA	GTC	576
167	Ser	Ser	His	Ile	Asn	Ser	Val	His	Val	His	Ile	Ser	Lys	Ser	Lys	Val	182
577	GGG	TGG	CTG	ATC	CAA	CTC	TTC	CAC	AAA	AAA	ATT	GAG	TCT	GCG	CTT	CGA	624
183	Gly	Trp	Leu	Ile	Gln	Leu	Phe	His	Lys	Lys	Ile	Glu	Ser	Ala	Leu	Arg	198
625	AAC	AAG	ATG	AAC	AGC	CAG	GTC	TGC	GAG	AAA	GTG	ACC	AAT	TCT	GTA	TCC	672
199	Asn	Lys	Met	Asn	Ser	Gln	Val	Cys	Glu	Lys	Val	Thr	Asn	Ser	Val	Ser	214
673	TCC	AAG	CTG	CAA	CCT	TAT	TTC	CAG	ACT	CTG	CCA	GTA	ATG	ACC	AAA	ATA	720
215	Ser	Lys	Leu	Gln	Pro	Tyr	Phe	Gln	Thr	Leu	Pro	Val	Met	Thr	Lys	Ile	230
721	GAT	TCT	GTG	GCT	GGA	ATC	AAC	TAT	GGT	CTG	GTG	GCA	CCT	CCA	GCA	ACC	768
231	Asp	Ser	Val	Ala	Gly	Ile	Asn	Tyr	Gly	Leu	Val	Ala	Pro	Pro	Ala	Thr	246

8/39

## FIGURE 3C

769	ACG	GCT	GAG	ACC	CTG	GAT	GTA	CAG	ATG	AAG	GGG	GAG	TTT	TAC	AGT	GAG	816
247	Thr	Ala	Glu	Thr	Leu	Asp	Val	Gln	Met	Lys	Gly	Glu	Phe	Tyr	Ser	Glu	262
817	AAC	CAC	CAC	AAT	CCA	CCT	CCC	TTT	GCT	CCA	CCA	GTG	ATG	GAG	TTT	CCC	864
263	Asn	His	His	Asn	Pro	Pro	Pro	Phe	Ala	Pro	Pro	Val	Met	Glu	Phe	Pro	278
865	GCT	GCC	CAT	GAC	CGC	ATG	GTA	TAC	CTG	GGC	CTC	TCA	GAC	TAC	TTC	TTC	912
279	Ala	Ala	His	Asp	Arg	Met	Val	Tyr	Leu	Gly	Leu	Ser	Asp	Tyr	Phe	Phe	294
913	AAC	ACA	GCC	GGG	CTT	GTA	TAC	CAA	GAG	GCT	GGG	GTC	TTG	AAG	ATG	ACC	960
295	Asn	Thr	Ala	Gly	Leu	Val	Tyr	Gln	Glu	Ala	Gly	Val	Leu	Lys	Met	Thr	310
961	CTT	AGA	GAT	GAC	ATG	ATT	CCA	AAG	GAG	TCC	AAA	TTT	CGA	CTG	ACA	ACC	1008
311	Leu	Arg	Asp	Asp	Met	Ile	Pro	Lys	Glu	Ser	Lys	Phe	Arg	Leu	Thr	Thr	326
1009	AAG	TTC	TTT	GGA	ACC	TTC	CTA	CCT	GAG	GTG	GCC	AAG	AAG	TTT	CCC	AAC	1056
327	Lys	Phe	Phe	Gly	Thr	Phe	Leu	Pro	Glu	Val	Ala	Lys	Lys	Phe	Pro	Asn	342
1057	ATG	AAG	ATA	CAG	ATC	CAT	GTC	TCA	GCC	TCC	ACC	CCG	CCA	CAC	CTG	TCT	1104
343	Met	Lys	Ile	Gln	Ile	His	Val	Ser	Ala	Ser	Thr	Pro	Pro	His	Leu	Ser	358
1105	GTG	CAG	CCC	ACC	GGC	CTT	ACC	TTC	TAC	CCT	GCC	GTG	GAT	GTC	CAG	GCC	1152
359	Val	Gln	Pro	Thr	Gly	Leu	Thr	Phe	Tyr	Pro	Ala	Val	Asp	Val	Gln	Ala	374
1153	CTT	GCC	GTC	CTC	CCC	AAC	TCC	TCC	CTG	GCT	TCC	CTC	TTC	CTG	ATT	GGC	1200
375	Leu	Ala	Val	Leu	Pro	Asn	Ser	Ser	Leu	Ala	Ser	Leu	Phe	Leu	Ile	Gly	390
1201	ATG	CAC	ACA	ACT	GGT	TCC	ATG	GAG	GTG	AGC	GCC	GAG	TCC	AAC	AGG	CTT	1248
391	Met	His	Thr	Thr	Gly	Ser	Met	Glu	Val	Ser	Ala	Glu	Ser	Asn	Arg	Leu	406

9/39

FIGURE 3D

249	GTT	GGA	GAG	CTC	AAG	CTG	GAT	AGG	CTG	CTC	CTG	GAA	CTG	AAG	CAC	TCA	1296
407	Val	Gly	Glu	Leu	Lys	Leu	Asp	Arg	Leu	Leu	Leu	Glu	Leu	Lys	His	Ser	422
297	AAT	ATT	GGC	CCC	TTC	CCG	GTT	GAA	TTG	CTG	CAG	GAT	ATC	ATG	AAC	TAC	1344
423	Asn	Ile	Gly	Pro	Phe	Pro	Val	Glu	Leu	Leu	Gln	Asp	Ile	Met	Asn	Tyr	438
345	ATT	GTA	CCC	ATT	CTT	GTG	CTG	CCC	AGG	GTT	AAC	GAG	AAA	CTA	CAG	AAA	1392
439	Ile	Val	Pro	Ile	Leu	Val	Leu	Pro	Arg	Val	Asn	Glu	Lys	Leu	Gln	Lys	454
393	GGC	TTC	CCT	CTC	CCG	ACG	CCG	GCC	AGA	GTC	CAG	CTC	TAC	AAC	GTA	GTG	1440
455	Gly	Phe	Pro	Leu	Pro	Thr	Pro	Ala	Arg	Val	Gln	Leu	Tyr	Asn	Val	Val	470
441	CTT	CAG	CCT	CAC	CAG	AAC	TTC	CTG	CTG	TTC	GGT	GCA	GAC	GTT	GTC	TAT	1488
471	Leu	Gln	Pro	His	Gln	Asn	Phe	Leu	Leu	Phe	Gly	Ala	Asp	Val	Val	Tyr	486
489	AAA	TGA	AGG	CAC	CAG	GGG	TGC	CGG	GGG	CTG	TCA	GCC	GCA	CCT	GTT	CCT	1536
487	Lys	***															488
537	GAT	GGG	CTG	TGG	GGC	ACC	GGC	TGC	CTT	TCC	CCA	GGG	AAT	CCT	CTC	CAG	1584
585	ATC	TTA	ACC	AAG	AGC	CCC	TTG	CAA	ACT	TCT	TCG	ACT	CAG	ATT	CAG	AAA	1632
633	TGA	TCT	AAA	CAC	GAG	GAA	ACA	TTA	TTT	ATT	GGA	AAA	GTG	CAT	GGT	GTG	1680
681	TAT	TTT	AGG	GAT	TAT	GAG	CTT	CTT	TCA	AGG	GCT	AAG	GCT	GCA	GAG	ATA	1728
729	TTT	CCT	CCA	GGA	ATC	GTG	TTT	CAA	TTG	TAA	CCA	AGA	AAT	TTC	CAT	TTG	1776
777	TGC	TTC	ATG	AAA	AAA	AAC	TTC	TGG	TTT	TTT	TCA	TGT	G				1813

10/39

FIGURE 4A  
FIGURE 4B  
FIGURE 4C

## FIGURE 4A

Human LBP Expression clone

1	GCT	AGC	CCA	CTG	CAC	TGG	GAA	TCT	AGG	ATG	GGG	GCC	TTG	GCC	AGA	GCC	48
1	NheI									Met	Gly	Ala	Leu	Ala	Arg	Ala	7
49	CTG	CCG	TCC	ATA	CTG	CTG	GCA	TTG	CTG	CTT	ACG	TCC	ACC	CCA	GAG	GCT	96
8	Leu	Pro	Ser	Ile	Leu	Leu	Ala	Leu	Leu	Leu	Thr	Ser	Thr	Pro	Glu	Ala	23
97	CTG	GGT	GCC	AAC	CCC	GGC	TTG	GTC	GCC	AGG	ATC	ACC	GAC	AAG	GGA	CTG	144
24	Leu	Gly	Ala	Asn	Pro	Gly	Leu	Val	Ala	Arg	Ile	Thr	Asp	Lys	Gly	Leu	39
145	CAG	TAT	GCG	GCC	CAG	GAG	GGG	CTA	TTG	GCT	CTG	CAG	AGT	GAG	CTG	CTC	192
40	Gln	Tyr	Ala	Ala	Gln	Glu	Gly	Leu	Leu	Ala	Leu	Gln	Ser	Glu	Leu	Leu	55
193	AGG	ATC	ACG	CTG	CCT	GAC	TTC	ACC	GGG	GAC	TTG	AGG	ATC	CCC	CAC	GTC	240
56	Arg	Ile	Thr	Leu	Pro	Asp	Phe	Thr	Gly	Asp	Leu	Arg	Ile	Pro	His	Val	71
241	GGC	CGT	GGG	CGC	TAT	GAG	TTC	CAC	AGC	CTG	AAC	ATC	CAC	AGC	TGT	GAG	288
72	Gly	Arg	Gly	Arg	Tyr	Glu	Phe	His	Ser	Leu	Asn	Ile	His	Ser	Cys	Glu	87
289	CTG	CTT	CAC	TCT	GCG	CTG	AGG	CCT	GTC	CCT	GGC	CAG	GGC	CTG	AGT	CTC	336
88	Leu	Leu	His	Ser	Ala	Leu	Arg	Pro	Val	Pro	Gly	Gln	Gly	Leu	Ser	Leu	103
337	AGC	ATC	TCC	GAC	TCC	TCC	ATC	CGG	GTC	CAG	GGC	AGG	TGG	AAG	GTG	CGC	384
104	Ser	Ile	Ser	Asp	Ser	Ser	Ile	Arg	Val	Gln	Gly	Arg	Tyr	Lys	Val	Arg	119
385	AAG	TCA	TTC	TTC	AAA	CTA	CAG	GGC	TCC	TIT	GAT	GTC	AGT	GTC	AAG	GGC	432
120	Lys	Ser	Phe	Phe	Lys	Leu	Gln	Gly	Ser	Phe	Asp	Val	Ser	Val	Lys	Gly	135
433	ATC	AGC	ATT	TCG	GTC	AAC	CTC	CTG	TTG	GGC	AGC	GAG	TCC	TCC	GGG	AGG	480
136	Ile	Ser	Ile	Ser	Val	Asn	Leu	Leu	Leu	Gly	Ser	Glu	Ser	Ser	Gly	Arg	151

11/39

FIGURE 4B

481	CCC	ACA	GTT	ACT	GCC	TCC	AGC	TGC	AGC	AGT	GAC	ATC	GCT	GAC	GTG	GAG	528
152	Pro	Thr	Val	Thr	Ala	Ser	Ser	Cys	Ser	Ser	Asp	Ile	Ala	Asp	Val	Glu	167
529	GTG	GAC	ATG	TCG	GGA	GAC	TTC	GGG	TGG	CTG	TTG	AAC	CTC	TTC	CAC	AAC	576
168	Val	Asp	Met	Ser	Gly	Asp	Phe	Gly	Trp	Leu	Leu	Asn	Leu	Phe	His	Asn	183
577	CAG	ATT	GAG	TCC	AAG	TTC	CAG	AAA	GTA	CTG	GAG	AGC	AGG	ATT	TGC	GAA	624
184	Gln	Ile	Glu	Ser	Lys	Phe	Gln	Lys	Val	Leu	Glu	Ser	Arg	Ile	Cys	Glu	199
625	ATG	ATC	CAG	AAA	TCC	GTG	TCC	TCC	GAT	CTA	CAG	CCT	TAT	CTC	CAA	ACT	672
200	Met	Ile	Gln	Lys	Ser	Val	Ser	Ser	Asp	Leu	Gln	Pro	Tyr	Leu	Gln	Thr	215
673	CTG	CCA	GTT	ACA	ACA	GAG	ATT	GAC	AGT	TTC	GCC	GAC	ATT	GAT	TAT	AGC	720
216	Leu	Pro	Val	Thr	Thr	Glu	Ile	Asp	Ser	Phe	Ala	Asp	Ile	Asp	Tyr	Ser	231
721	TTA	GTG	GAA	GCC	CCT	CGG	GCA	ACA	GCC	CAG	ATG	CTG	GAG	GTG	ATG	TTT	768
232	Leu	Val	Glu	Ala	Pro	Arg	Ala	Thr	Ala	Gln	Met	Leu	Glu	Val	Met	Phe	247
769	AAG	GGT	GAA	ATC	TTT	CAT	CGT	AAC	CAC	CGT	TCT	CCA	GTT	ACC	CTC	CTT	816
248	Lys	Gly	Glu	Ile	Phe	His	Arg	Asn	His	Arg	Ser	Pro	Val	Thr	Leu	Leu	263
817	GCT	GCA	GTC	ATG	AGC	CTT	CCG	GAG	GAA	CAC	AAC	AAA	ATG	GTC	TAC	TTT	864
264	Ala	Ala	Val	Met	Ser	Leu	Pro	Glu	Glu	His	Asn	Lys	Met	Val	Tyr	Phe	279
865	GCC	ATC	TCG	GAT	TAT	GTC	TTC	AAC	ACG	GCC	AGC	CTG	GTT	TAT	CAT	GAG	912
280	Ala	Ile	Ser	Asp	Tyr	Val	Phe	Asn	Thr	Ala	Ser	Leu	Val	Tyr	His	Glu	295
913	GAA	GGA	TAT	CTG	AAC	TTC	TCC	ATC	ACA	GAT	GAC	ATG	ATA	CCG	CCT	GAC	960
296	Glu	Gly	Tyr	Leu	Asn	Phe	Ser	Ile	Thr	Asp	Asp	Met	Ile	Pro	Pro	Asp	311
961	TCT	AAT	ATC	CGA	CTG	ACC	ACC	AAG	TCC	TTC	CGA	CCC	TTC	GTC	CCA	CGG	1008
312	S	r	Asn	Ile	Arg	Leu	Thr	Lys	Ser	Phe	Arg	Pro	Phe	Val	Pro	Arg	327



12/39

## FIGURE 4C

1009	TTA	GCC	AGG	CTC	TAC	CCC	AAC	ATG	AAC	CTG	GAA	CTC	CAG	GGA	TCA	GTG	1056
328	Leu	Ala	Arg	Leu	Tyr	Pro	Asn	Met	Asn	Leu	Glu	Leu	Gln	Gly	Ser	Val	343
1057	CCC	TCT	GCT	CCG	CTC	CTG	AAC	TTC	AGC	CCT	GGG	AAT	CTG	TCT	GTG	GAC	1104
344	Pro	Ser	Ala	Pro	Leu	Leu	Asn	Phe	Ser	Pro	Gly	Asn	Leu	Ser	Val	Asp	359
1105	CCC	TAT	ATG	GAG	ATA	GAT	GCC	TTT	GTG	CTC	CTG	CCC	AGC	TCC	AGC	AAG	1152
360	Pro	Tyr	Met	Glu	Ile	Asp	Ala	Phe	Val	Leu	Leu	Pro	Ser	Ser	Ser	Lys	375
1153	GAG	CCT	GTC	TTC	CGG	CTC	AGT	GTG	GCC	ACT	AAT	GTG	TCC	GCC	ACC	TTG	1200
376	Glu	Pro	Val	Phe	Arg	Leu	Ser	Val	Ala	Thr	Asn	Val	Ser	Ala	Thr	Leu	391
1201	ACC	TTC	AAT	ACC	AGC	AAG	ATC	ACT	GGG	TTC	CTG	AAG	CCA	GGA	AAG	GTA	1248
392	Thr	Phe	Asn	Thr	Ser	Lys	Ile	Thr	Gly	Phe	Leu	Lys	Pro	Gly	Lys	Val	407
1249	AAA	GTG	GAA	CTG	AAA	GAA	TCC	AAA	GTT	GGA	CTA	TTC	AAT	GCA	GAG	CTG	1296
408	Lys	Val	Glu	Leu	Lys	Glu	Ser	Lys	Val	Gly	Leu	Phe	Asn	Ala	Glu	Leu	423
1297	TTG	GAA	GCG	CTC	CTC	AAC	TAT	TAC	ATC	CTT	AAC	ACC	TTC	TAC	CCC	AAG	1344
424	Leu	Glu	Ala	Leu	Leu	Asn	Tyr	Tyr	Ile	Leu	Asn	Thr	Phe	Tyr	Pro	Lys	439
1345	TTC	AAT	GAT	AAG	TTG	GCC	GAA	GGC	TTC	CCC	CTT	CCT	CTG	CTG	AAG	CGT	1392
440	Phe	Asn	Asp	Lys	Leu	Ala	Glu	Gly	Phe	Pro	Leu	Pro	Leu	Leu	Lys	Arg	455
1393	GTT	CAG	CTC	TAC	GAC	CTT	GGG	CTG	CAG	ATC	CAT	AAG	GAC	TTC	CTG	TTC	1440
456	Val	Gln	Leu	Tyr	Asp	Leu	Gly	Leu	Gln	Ile	His	Lys	Asp	Phe	Leu	Phe	471
1441	TTG	GGT	GCC	AAT	GTC	CAA	TAC	ATG	AGA	GTT	TGA	GGA	CAA	GAA	AGA	TGA	1488
472	Leu	Gly	Ala	Asn	Val	Gln	Tyr	Met	Arg	Val	***						482
1489	AGC	TTG	CTC	GAG													1500

XhoI



14/39

**FIGURE 5B**

	30	40	50
house	Q R E L Y R I T L P D F S G D D Q	Q R E L Y R I T L P D F S G D D Q	Q R E L Y R I T L P D F S G D D Q
rabbit	Q R K L L E V T L P D F S G D D Q	Q R K L L E V T L P D F S G D D Q	Q R K L L E V T L P D F S G D D Q
human	Q S E L L R I T L P D F S G D D Q	Q S E L L R I T L P D F S G D D Q	Q S E L L R I T L P D F S G D D Q
human	Q K E L K R I T L P D F S G D D Q	Q K E L K R I T L P D F S G D D Q	Q K E L K R I T L P D F S G D D Q
ovine	Q K E L K R I T L P D F S G D D Q	Q K E L K R I T L P D F S G D D Q	Q K E L K R I T L P D F S G D D Q
	60	70	80
house	Y E F H S L E I Q N C E L R G S	Y E F H S L E I Q N C E L R G S	Y E F H S L E I Q N C E L R G S
rabbit	Y K F H S L E I Q N C E L R G S	Y K F H S L E I Q N C E L R G S	Y K F H S L E I Q N C E L R G S
human	Y E F H S L E I Q N C E L R G S	Y E F H S L E I Q N C E L R G S	Y E F H S L E I Q N C E L R G S
human	Y S F H S L E I Q N C E L R G S	Y S F H S L E I Q N C E L R G S	Y S F H S L E I Q N C E L R G S
ovine	Y S F H S L E I Q N C E L R G S	Y S F H S L E I Q N C E L R G S	Y S F H S L E I Q N C E L R G S
	90	100	110
house	L S L D I S D A Y I H V R G S	L S L D I S D A Y I H V R G S	L S L D I S D A Y I H V R G S
rabbit	L S L D I S D A Y I H V R G S	L S L D I S D A Y I H V R G S	L S L D I S D A Y I H V R G S
human	L K F S I S N A N I K I S G K W	L K F S I S N A N I K I S G K W	L K F S I S N A N I K I S G K W
human	L D L S I R D A S I K I R G K W	L D L S I R D A S I K I R G K W	L D L S I R D A S I K I R G K W
ovine	L D L S I R D A S I K I R G K W	L D L S I R D A S I K I R G K W	L D L S I R D A S I K I R G K W









19/39


FIGURE 6

10	20	30	40	50	60
- MGALARA	ILLLALLTBT	PEARQANPGL	VARITDKGLQ	YAAQEGLLAL	QSELLRITLP
70	80	90	100	110	120
DFTGDLRIPH	VGRGRYEFHS	LNIHSCCELLH	SALRPVPGQG	LSLSISDSSI	RVQGRWKVRK
130	140	150	160	170	180
SFFKLGQSF	VSVKGISISV	NLLLGSESSG	RPTVTASSCS	SDIADVEVDM	SGDLGWLLNL
190	200	210	220	230	240
FHNQIESKFQ	KVLESRICEM	IQKSVSSDLQ	PYLQTLPTTT	EIDSVAGINY	GLVAPPATTA
250	260	270	280	290	300
ETLDVQMKGE	FYSENHNPP	PFAPPVMEFP	AAHDMVYLG	LSDYFFNTAG	LVYQEAGVLK
310	320	330	340	350	360
MTLRDDMIPK	ESKFRLLTKF	FGTFLPEVAK	KFPNMKIQIH	VSASTPPHLS	VQPTGLTFYP
370	380	390	400	410	420
AVDVQALAVL	PNSSLASLFL	IGMHTTGSME	VSAESNRLVG	ELKLDRLLE	LKHSNIGPFP
430	440	450	460	470	479
VELLDIMNY	IVPILVLPRV	NEKLQKGFPL	PTPARVQLYN	VVLQPHQNFL	LFGADVVK* -C



20/39


FIGURE 7



—●— BPI  
—○— LBP (NCY102)  
—■— L1-197(I43→V)B<sub>200-456</sub>(N206→D) (NCY103)  
—▲— B1-199L<sub>200-456</sub> (NCY104)

21/39


FIGURE 8



- BPI
- LBP (NCY102)
- L<sub>1-197</sub>(I43→V)B<sub>200-456</sub>(N206→D) (NCY103)
- ▲— B<sub>1-199</sub>L<sub>200-456</sub> (NCY104)
- ◆— B<sub>(S351→A)</sub> (NCY105)

22/39

FIGURE 9




—□— BPI + SERUM

—♦— L(1-197(I43→V)B<sub>200-456</sub>(N206→D)(NLY103)  
+ SERUM


23/39

FIGURE 10



24/39


FIGURE 11



- BPI (5mg/kg)
- LBP (NCY102) (5mg/kg)
- LI-197 (I43→V1) B<sub>200-456</sub> (NCY103) (2.5mg/kg)
- BI-199 L<sub>200-456</sub> (NCY104) (1mg/kg)

25/39

FIGURE 12



26/39

FIGURE 13A






FIGURE 13B



27/39

FIGURE 13C





28/39

FIGURE 14A






FIGURE 14B




29/39

FIGURE 15



30/39

FIGURE 16



- LBP (NCY102) (n=3)
- ▲— L1-198B<sub>202-275</sub>L<sub>274-456</sub> (NCY135) (n=3)
- L1-134B<sub>136-275</sub>L<sub>274-456</sub> (NCY134) (n=1)
- -□- - L1-275B<sub>278-456</sub> (NCY116) (n=3)
- L1-359B<sub>360-456</sub> (NCY117) (n=3)

31/39

FIGURE 17A





FIGURE 17B



32/39

FIGURE 17C






FIGURE 17D




33/39

FIGURE 17E




34/39

FIGURE 17F



35/39

FIGURE 17G




5mg/kg compound injected i.v. at t=0



36/39

FIGURE 17H



37/39

**FIGURE 18**


**Lane Number**

**1 2 3 4 5 6 7 8 9 10 11 12**




38/39

FIGURE 19



39/39

FIGURE 20



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06134**A. CLASSIFICATION OF SUBJECT MATTER**IPC(6) : C07H 15/12; C12P 21/06; A61K 39/00, 38/00; C07K 1/00  
US CL : 530/300, 350; 435/69.1, 320.1, 252.3; 536/22.1, 22.3; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 350; 435/69.1, 320.1, 252.3; 536/22.1, 22.3; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
DIALOG, APS**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,94/25476 A (SCOTT et al) 10 November 1994, see entire document.	1-38, 42
X	WO 94/18323 A (THEOFAN et al) 18 August 1994, see entire document.	14, 31, 32,
X	US 5,348,942 A (LITTLE et al) 20 September 1994, column 5, lines 40-45, column 7, lines 3-23.	14, 31, 32, 33

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  
08 JUNE 1996Date of mailing of the international search report  
16 JUL 1996Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20531Authorized officer  
H. F. SIDBERRY

C Ts my for

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06134

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
14-38, 42
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06134

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-4, 9-13, 43, drawn to method of in vivo detection of a site of Gram-negative bacterial infection, labelled endotoxin neutralizing polypeptide, composition, classified in Classes 514, subclass 2.

Group II, claim(s) 5-8, drawn to a method of in vitro detection of a Gram-negative bacterial infection, classified in Class 436, subclass 517.

Group III, claim(s) 14-38, 42 drawn to endotoxin-neutralizing polypeptides, method of making the polypeptides classified in Classes 530 and 435, subclasses 300, 350; 69.1.

Group IV, claims 39-41, drawn to DNA encoding a recombinant endotoxin binding polypeptide, vector and host cells, classified in Classes 536 and 435, subclasses 22.1, 23.1, 23.5 and 320.1 and 69.1.

Group V, claims 44, 45, drawn to methods of treatment using an endotoxin neutralizing polypeptide, classified in Class 514, subclass 2.

The inventions listed as Groups I, II, III, IV, V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is directed to a labelled endotoxin neutralizing polypeptide which is not defined. The polypeptide may be a variant of BPI or LPS in that the amino acid must not be identical to the amino acid sequences of either BPI or LPS. The methods of Group I and II are in vitro or in vivo, the method steps will differ in parameter, reagents and method steps.

The inventions of Group III are directed to polypeptides which are different from that required in Groups I and II to perform the methods of detection. The polypeptide of Group III is not the special technical feature set forth in the inventions of Group I and II. Group IV is directed to DNA which encodes an endotoxin neutralizing polypeptide. However, variants of BPI and LPS occur spontaneously or may be achieved by chemical modifications.

Group V is directed to other methods which use the endotoxin neutralizing polypeptide, but not one which is labeled as of Groups I and II.

The special technical feature which links the inventions is known in the art, for Groups I, II and III, as SCOTT et al WO 94-25476, discloses an endotoxin neutralizing polypeptide wherein the serine at 351 has been changed to alanine. (see page 18, lines 22-27. Other variants of BPI are disclosed by SCOTT et al at page 35.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

(a) species of BPI variants which are chimeric: claims 29-35

(b) species of BPI variants which have substitutions: 14-28, 36-38.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the first species are directed to constructs comprising BPI or LPS and/or an immunoglobulin fragment. The second species is directed to BPI variants which have substitutions in the amino acid sequence. The variants have only substitutions. The chimeras are comprised of the LPS or the immunoglobulin fragment and thus are comprised of an element not needed in the variant BPI proteins.